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Abstract 
Synthetic protocols involving easy handling process, atom economy, ambient reaction 
conditions, short reaction times, inexpensive and less hazardous catalyst always have been 
attractive. Multi-component reaction is a chemical reaction, in which three or more starting 
materials react to form the product in an atom economy manner and ease of access to complex 
molecules in one-pot certainly belong to this class. A contemporary challenge in the world is 
environmental pollution. Multi component reactions are certainly one of the solutions for this 
problem due to the less release of chemical wastage compared with classical bicomponent 
reaction protocols and it is being considered as one of the green technology. I have also tried to 
use water as a reaction solvent to synthesize heterocyclic compounds because water is cheaper, 
green solvent and highly abundant in nature. I have synthesized various valuable heterocyclic 
compounds using multicomponent reactions. 
Compounds possessing pyrrolo[2,3-c]pyridone backbone have been used to control the 
cell proliferation in breast cancer and p38 kinase inhibitors. Wang Le et. al., also have reported 
molecules having pyrrolo[2,3-c]pyridone backbone as BRD4 receptor inhibitors to control breast 
cancer. Considering the importance of these molecules, we have demonstrated an efficient, mild 
and multicomponent protocol for the synthesis of novel heterocyclic compounds possessing 
pyrrolo[2,3-c]pyridone backbone by using Ugi four component reaction and post condensation of 
Ugi adduct. This method offers several advantages such as easy handling procedure, atom 
economy, short reaction time and huge molecular library can be synthesized by changing the 
substituents on four independent starting materials. In previous reported methods for pyrrolo[2,3-
c]pyridones, expensive metal catalysts were used, where as in present method we used 
inexpensive PTSA catalyst. Various anilines substituted with Iodo, bromo, chloro, methyl, 
methoxy at different positions on aniline were used in Ugi 4CR. And also phenyl glyoxylic acids 
substituted with methoxy, ethoxy, methyl and chloro were used in combinations with t-butyl and 
cyclohexyl isocyanides. In all cases the reaction proceeded smoothly and yielded the 
corresponding pyrrolo[2,3-c]pyridone derivatives in good to excellent yields. Considering these 
advantages we hope this methodology will be useful for medicinal chemists in drug discovery 
process. All the products were characterized by using NMR (1H and 13C) spectroscopy and 
FAB mass. One of the products was further characterized with X-ray diffraction analysis. 
Coumarin analogs having both coumarin and furan heterocycles have gained the 
considerable attention of researchers due to their significant properties as anti-leishmania 
panamensis, dyes and fluorescent sensors. Coumarin analogs with furan heterocycle isolated 
from the plants origin such as microminutin, micromelin, psoralen, 8-methoxypsoralen have 
important properties in medicinal chemistry and bio photochemistry. It is well documented that 
by introducing a heteroaromatic substituent at 3-position the absorption and emission maxima of 
coumarin scaffold can be improved because of extended pi conjugation and consequently their 
optoelectronic properties can be improved. Based on this phenomenon a variety of 3-heteroaryl 
coumarin derivatives have been synthesized and evaluated for their optoelectronic properties. 
Considering the broad range of applications of furyl coumarin derivatives, we have 
demonistrated an efficient and facile synthesis of 3-furyl coumarin derivatives by reaction of 4-
chloro-3-formylcoumarin, secondary amines, dialkyl acetylenedicarboxylates and diversely 
substituted isocyanides using four component one pot reaction. All the products were isolated as 
yellow color fluorescent solids by column chromatography in quantitative yield and 
characterized with 1H NMR, C13 NMR, IR and FAB mass. 
Spiro compounds having dipyrrole namely Amathaspiramide A, Mytraginine 
psuedoindoxyl as shown below was proven to have prominent antiviral and anticancer 
properties. Very few reports were there in the literature for the synthesis of spiro [indole-2,2’-
pyrroles] bearing spiro carbon at C-2 position. Considering this as an opportunity, we have 
developed an efficient and facile method for the synthesis of novel spiro[indole-2,2'-pyrroles] 
from N-methyl-3-isatin imines, t-butyl isocyanide and dialkyl acetylenedicarboxylate has been 
achieved by [3+2] cyclo addition reaction. The notable advantages of this protocol are 
operational simplicity, easily available starting materials, available diversity of each component, 
catalyst free and easy work procedure employed. We believed in this protocol will help in 
developing novel spiro heterocyclic compounds using C-2 carbon atom of isatin. All the products 
were purified by column chromatography as yellow solids and confirmed with 1H NMR, 
13CNMR, FAB mass, IR. One of the compound was further confirmed with X-ray analysis. 
Imidazo[1,2-a]pyridines have been valuable to organic and medicinal chemists due to the 
interesting structure and numerous applications in pharmaceutical Industry. The molecules 
possessing imidazo[1,2-a]pyridine core structure have been used as  anticancer, anti-
inflammatory,  antibacterial, antiprotozonal and antiviral agents. Additionally, they were also 
used for the treatment of gastric disease and heart disease. They have been found in drug 
candidates such as Minodronic acid used for the treatment of osteoporosis, Zolpidem used for the 
treatment of insomnia and some brain disorders, Zolmidine used for the treatment of peptic 
ulcers and gastro esophageal reflux disease and Olprinone used for the treatment of acute heart 
failure. Considering these applications, New coumarin derivatives having imidazo[1,2-a]pyridine 
heterocycle moiety were synthesized by the condensation of 4-morpholino-3-formyl coumarin, 
diversely substituted 2-amino pyridine and isocyanides under catalyst free, water mediated 
reaction conditions. All the products were characterized by using IR, NMR (1H and 13C) 
spectroscopy and HRMS spectrometry. Product 4b was further characterized with X-ray 
diffraction analysis. All the products have showed UV-Visible absorbance in between 234 nm to 
248 nm and emissions were observed in between 412 nm to 544 nm.  
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Chapter 1 
Introduction 
1. Overview of multicomponent reactions 
Multi-component reaction is a chemical reaction, in which more than two starting materials 
react to form the product in an atom economy manner. Multi-component reactions belong to 
green chemistry. Using multi-component synthesis methods many complex heterocyclic 
molecules have been synthesized with ease, atom economy manner, therefore it is believed that 
multi-component methods reduce the chemical waste by reducing the number of chemical 
synthesis steps.1-4 In the contemporary world one of the major global problems is environmental 
pollution. Pharmaceutical industry, which is dedicated for the drug discovery is one of the major 
polluter causing environmental pollution by releasing chemical waste into the environment. So, 
the major challenge for the pharmaceutical industries is to keep focus on developing sustainable, 
environmental benign chemical methods for the synthesis of pharmaceutically active 
compounds. In this context, multi-component reactions, in which chemical waste is considerably 
reduced by reducing the number of chemical synthesis steps, attracted the chemists. On the other 
hand, water mediated and catalyst free protocols for the synthesis valuable heterocyclic 
compounds have been attracting great attention because such methodologies also reduces the 
generation of organic waste, water is abundant, inexpensive, non toxic and environmental 
benign solvent.5 Another notable advantage of multi-component reactions is that within short 
reaction time huge molecular library can be synthesized by varying substituent on each 
individual starting material. Because of these advantages, multi-component reactions have been 
extensively used in medicinal chemistry and materials chemistry.6    
 In this context Isocyanide based multi-component reactions such as passerini three 
component reaction,7 Ugi four-component reaction and intramolecular Ugi four centre three-
component reactions have been extensively used for the synthesis of various heterocyclic 
molecules.8 In my graduation research, I have used Ugi four-component reaction followed by 
the condensation reaction for the synthesis of various substituted pyrrolo[2,3-c]pyridone analog 
derivatives.  
 Another notable isocyanide based multicomponent reaction is that addition of isocyanides 
to electron deficient alkynes such as dialkylacetylene dicarboxylate generated a 1,3-dipolar 
intermediate,9-10 which was captured in situ by 1,2-dipolar nucleophiles such as carbonyl 
functional groups generated a furan heterocycles was extensively used for the synthesis of 
various substituted furan derivatives.11 In my graduation research I have employed this strategy 
and synthesized various substituted 3-furyl coumarin derivatives and evaluated their 
photophysical properties.  
 Another important multicomponent reaction is Groebke-Blackburn-Bienayme reaction, 
involved one-pot condensations of aldehydes, isonitriles, and 2-aminopyridines generates the 
imidazo[1,2-a]pyridine derivatives in one pot. It is the well known and extensively used 
multicomponent reaction for the synthesis of imidazo[1,2-a]pyridine derivatives.12-15 This 
reaction was proved to compatible to variety of aromatic and heteroaromatic aldehydes. In my 
graduation research, I have used 4-thiomorpholino-3-formyl coumarin as aldehyde component 
and performed Groebke-Blackburn-Bienayme type condensation to synthesisze imidazo[1,2-
a]pyridine derivatives in aqueous medium under refluxing conditions. 
 
2. Pyrrolo[2,3-c]pyridone derivatives 
Pyrrolo[2,3-c]pyridone is a fused heterocyclic system possessing both pyrrole and 
pyridone. Compounds possessing pyrrolo[2,3-c]pyridone backbone have been used to control the 
cell proliferation in breast cancer and p38 kinase inhibitors.16-17 Wang Le et. al., also have 
reported molecules having pyrrolo[2,3-c]pyridone backbone as BRD4 receptor inhibitors to 
control breast cancer. Despite very important properties of these molecules in medicinal 
chemistry, not much research has been done for the development of efficient protocols to their 
synthesis. Vander Eycken et. al., have reported the synthesis of pyrrolo[2,3-c]pyridinone with 
carbonyl group at slightly different position employing Ugi reaction followed by gold(I) 
catalyzed intramolecular hydroarylation using N-methyl-2-pyrrole carbaldehyde and N-methyl-
3-pyrrole carbaldehyde.18-19However this methodology requires longer reaction times (72h 
including two steps) and expensive gold catalysts were employed for the cyclization step. As part 
of my graduation research, herein we established a simple procedure for the synthesis of 
pyrrolo[2,3-c]pyridones using Ugi reaction followed post cyclization of Ugi adduct under acidic 
conditions.  
3. 3-Furyl coumarin derivatives
Coumarin analogs have been considered as important class of heterocyclic compounds 
due to their significant applications as anticoagulant,20 antibacterial,21 antihypertensive,22 anti-
tubercular,23 antifungal,24 anticancer,25 HIV protease inhibition,26 Laser dyes and fluorescent 
properties.27 Similarly Furan ring is found in many pharmaceutically important substances like 
furanose form in carbohydrate, alkaloid pylocarpine and furacilin antibiotics. Coumarin analogs 
having both coumarin and furan heterocycles have gained the considerable attention of 
researchers due to their significant properties as anti-leishmania panamensis,28 dyes and 
fluorescent sensors.29 Coumarin analogs with furan heterocycle isolated from the plants origin 
such as microminutin, micromelin, psoralen, 8-methoxypsoralen have important properties in 
medicinal chemistry and bio photochemistry.30 It is well documented that by introducing a 
heteroaromatic substituent at 3-position the absorption and emission maxima of coumarin 
scaffold can be improved because of extended pi conjugation and consequently their 
optoelectronic properties can be improved.31 Based on this phenomena a variety of 3-heteroaryl 
coumarin derivatives have been synthesized and evaluated for their optoelectronic properties.32 
3-furyl coumarin falls under this class with extended pi conjugation. Thus the structural features 
and the wide spectrum of applications of furyl coumarin analogs have prompted the intense 
research by the chemists to develop novel, simple and efficient methods for their synthesis.  
4. Spiro[indole-2,2'-pyrrole] derivatives 
  Spiro compounds having both indole and pyrrole nucleus is found to be the key structural 
unit in many natural products such as Spirotriprostrain A, Spirotriprostrain B and Horsfiline, 
which were proven to have anticancer activity. Spiro compounds having dipyrrole namely 
Amathaspiramide A, Mytraginine psuedoindoxyl as shown below was proven to have prominent 
antiviral and anticancer properties.33  
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In my graduation research, we have demonstrated a novel three component [3+2] cyclo addition 
reaction for the synthesis of spiro [indole-pyrazoles] using C-2 carbon atom of isatin.  
5. imidazo[1,2-c]pyridine derivatives possessing coumarin   
imidazo[1,2-a]pyridines have been valuable to organic and medicinal chemists due to the 
interesting structure and numerous applications in pharmaceutical Industry.34The molecules 
possessing imidazo[1,2-a]pyridine core structure have been used as  anticancer, anti-
inflammatory,  antibacterial, antiprotozonal and antiviral agents. Additionally, they were also 
used for the treatment of gastric disease and heart disease. They have been found in drug 
candidates such as Minodronic acid, Zolpidem, Zolmidine. In the present study we have used 4-
morpholino-3-formyl coumarin as aldehyde component and performed Groebke-Blackburn-
Bienayme type condensation to synthesisze imidazo[1,2-a]pyridine derivatives. As part of our 
ongoing research for the synthesis bioactive novel heterocycles using isocyanide based 
multicomponent reactions, here in we report the one-pot multicomponent synthesis of novel 
imidazo[1,2-a]pyridine derivatives having 4-hydroxy coumarin. 
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Chapter 2 
Efficient synthesis of novel pyrrolo[2,3-c]pyridone 
derivatives using Ugi for-component reaction followed by 
acid assisted condensation reaction 

Abstract:  
An efficient, mild and multicomponent protocol for the synthesis of novel heterocyclic 
compounds possessing pyrrolo[2,3-c]pyridone backbone was achieved by using Ugi 4CR and 
post condensation of Ugi adduct. This method offers many advantages such as easy handling 
procedure, atom economy, short reaction time and huge molecular library can be synthesized by 
changing the substituents on four independent starting materials. This methodology was also 
successfully employed to the electron deficient anilines and phenyl glyoxylic acids having CF3 
group. All the products were characterized by using NMR (1H and 13C) spectroscopy and FAB 
mass. Product 6g was further characterized with X-ray diffraction analysis. 
1. Introduction 
Synthetic protocols involving easy handling process, atom economy, ambient 
reaction conditions, short reaction times, inexpensive and less hazardous catalyst always 
have been attractive. Multicomponent reaction is a chemical reaction, in which three or 
more starting materials react to form the product in an atom economy manner and ease of 
access to complex molecules in one-pot certainly belong to this class.1-2 Ugi reaction is a 
multicomponent reaction involving the condensation of aldehydes, amines, carboxylic 
acids and isocyanides to form the corresponding diamides adducts. Ugi multicomponent 
reaction have emerged as an important tool for the chemists because of its vast 
applications in chemistry.3 Post condensation transformations of Ugi product also 
emerged as important tools to the chemists due to numerous applications in the synthesis 
of biologically important fused heterocyclic systems.4-10 For example, the 
pharmacologically important 1,4-benzodiazepin-2-one analogs were achieved by using 
Ugi four component reaction followed by deprotection and cyclization reactions. Also 
various fused tetrazoles, peptidomimetic 3-carboxamide-1,4-benzodiazepin-5-ones were 
reported by using Ugi reaction and post modification of Ugi adduct.11-13 Pyrrolo[2,3-
c]pyridone is a fused heterocyclic system possessing both pyrrole and pyridone.   
Compounds possessing pyrrolo[2,3-c]pyridone backbone have been used to control the 
cell proliferation in breast cancer and p38 kinase inhibitors.14-15 Wang Le et. al., also have 
reported molecules having pyrrolo[2,3-c]pyridone backbone as BRD4 receptor inhibitors to 
control breast cancer.15 However not much research have been done for the development of 
efficient protocols to get these molecules. Vander Eycken et. al., have reported the synthesis of 
pyrrolo[2,3-c]pyridinone with carbonyl group at slightly different position employing Ugi 
reaction followed by gold(I) catalyzed intramolecular hydroarylation using N-methyl-2-pyrrole 
carbaldehyde and N-methyl-3-pyrrole carbaldehyde.16-17However this methodology requires 
longer reaction times (72h including two steps) and expensive gold catalysts were employed for 
the cyclization step. 
      As part of our continuous research towards the development of efficient methods for 
the synthesis of valuable heterocyclic systems using multicomponent reactions, herein we 
established a simple procedure for the synthesis of pyrrolo[2,3-c]pyridones using Ugi 
reaction followed post cyclization of Ugi adduct under acidic conditions. Earlier, we have 
reported the synthesis of novel spiro[indol-2,2’-pyrroles] and 3-furyl coumarin 
derivatives using isocyanide based multicomponent reactions.18-19 
2. RESULTS AND DISCUSSION 
We took 2-formyl pyrrole (1), t-Butyl isocyanide (2a), phenyl glyoxylic acid (3a) 
and 4-bromo aniline (4a) as model substrates to demonstrate Ugi 4-CR. The Ugi 4-CR 
was successfully performed by using 2-formyl pyrrole (1), t-Butyl isocyanide (2a), 
phcenyl glyoxylic acid (3a) and 4-bromo aniline (4a) in methanol at ambient temperature 
for 60 min. 
 
 
 
 


Scheme 1 Synthesis of Ugi adduct 5a 
The precipitated white solid was filtered off, washed with ice cooled methanol (3 ml). 
This adduct was further investigated to synthesize pyrrolo[2,3-c]pyridone. 
The Ugi adduct was further subjected to condensation under different reaction 
conditions in order to get the pyrrolo[2,3-c]pyridone analogs. The results were 
summarized in Table 1. While the reaction was conducted under basic reaction conditions 
using NaOH, Na2CO3, K2CO3 and NaH in methanol solvent using at 50oC for 24h (Table 
1. Entrys 1-4), traces of the expected product formation was observed. The condensation 
of Ugi adduct was smoothly happened under acidic reaction condition. When the PTSA 
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was employed as catalyst in methanol at 50oC for 1h, the yield of the product was 96% 
(Table 1. Entry 5). When 50 mol% PTSA was used as catalyst same amount of product 
formation was observed (Table 1. Entry 6). 
 
Table 1. Optimization of the reaction conditions for condensation of the Ugi adducta 
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cEntry 6 and 7, 50 mol% and 10 mol% PTSA catalyst was loaded respectively 
On the other hand, When 10 mol% PTSA was used as catalyst 70% of product 
formation was observed in 5h (Table 1. Entry 7). Ugi adduct condensation was also 
occurred using acetic acid, TBAB. The yield of the product was 60 % and 10 % 
respectively (Table 1. Entrys 8, 9). From the optimization reaction conditions 50 mol% 
PTSA was found to be the best catalyst to carry out the condensation of Ugi adduct to 
pyrrolo[2,3-c]pyridone derivative with significantly short reaction time and quantitative 
yield. To explore the tolerance of these conditions, the reaction was further explored to 
different Ugi adducts synthesized by varying anilines, phenyl glyoxylic acids and 
isocyanides. The results were summarized in Table 2. 
                           Table 2. Synthesis of pyrrolo[2,3-c]pyridone analogs 
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ayields refer to precipetated solids and all the reactions were run on 1 mmol scale 
byields refer to precipetated solids 
        Various anilines substituted with Iodo, bromo, chloro, methyl, methoxy at different 
positions on aniline were used in Ugi 4CR. And also phenyl glyoxylic acids substituted with 
methoxy, ethoxy, methyl and chloro were used in combinations with t-butyl and cyclohexyl 
isocyanides. We also have attempted the reaction using anilines and phenyl glyoxylic acids 
having electron-deficient aryl group, such as -ArNO2 and -ArCF3. When the reaction was 
performed with aniline having CF3 group and phenyl glyoxylic acid having CF3 group, the 
reaction proceeded smoothly and yielded the corresponding pyrrolo[2,3-c]pyridone derivatives in 
91 % (Entry 25) and 81 % (Entry 26) respectively. However, when the reaction was performed 
with aniline having NO2, Ugi 4CR itself did not happened, may due to the presence of NO2 
group imine formation was not happened. When the reaction was performed with phenyl 
glyoxylic acids having NO2 group, Ugi 4CR proceeded smoothly, but cyclization step was not 
happened even after refluxing for 14h. In all the cases Ugi 4CR and post condensation of Ugi 
adduct proceeded smoothly, resulted the corresponding Ugi adduct and pyrrolo[2,3-c]pyridone in 
quantitative yields (91-98%). First step (Ugi 4CR) of this protocol, all the products were 
precipitated as white color solids and second step that is PTSA catalyzed post condensation of 
Ugi adduct, after the reaction on addition of water the fi
products were characterized by using NMR (1H and 13C) spectroscopy and FAB mass 
spectrometry. One of the final product 
analysis. Good crystals suitable for X
evaporation method in MeOH solvent. The ortep diagram of the molecule 
1. One water molecule was found in crystal structure of final product 
molecule was not shown in ortep diagram.
Figure 1. Ortep diagram of final product 
From the experimental results, the possible mechanism for the formation of pyrrolopyridone was 
depicted as follows. To explain the possible pathway for the formation of pyrrolopyridone, the 
Ugi adduct of the final compound 
formation of product 6a was shown in 
PTSA catalyst. Initially α-keto group of Ugi adduct was protonated and subsequent
electrophilic addition on pyrrole ring generated
undergoes dehydration under same catalytic condition yields the final product 
nal products were precipitated. All the 
6g was further characterized with X
-ray diffraction analysis were obtained using slow 
6g is
6g. For clarity the water 
 
 
6g, ellipsoids were drawn with 50% probability
6a was taken as model substrate. The possible path way for the 
scheme 2. Ugi adduct 5a was activated by the addition of 
 the intermediate I. This intermediate 
6a
-ray diffraction 
 shown in Figure 
 
ly 
I, 
.   
N
H
N
O
O
NH
Br
5a
N
H
N
O
O
NH
Br
O
Ph
PTSA
H
Ph OH
H
H
H
NN
O
O
HN
Br
PhHO
H
PTSA H
N
H
N
O
O
NH
Br
Ph OH2
H
N
H
N
O
O
NH
Br
6a
 
Scheme 1 Possible reaction mechanism for the synthesis of pyrrolo[2,3-c]pyridone 
3. Experimental section 
General 
 All reagents were purchased from TCI and Sigma Aldrich and used without further purification. 
All the products were characterized by 1H NMR, C13 NMR, IR, and Fab-Mass analysis. The 
NMR spectra were recorded on a Bruker AMX-500 MHz instrument at room temperature in 
DMSO-d6 using TMS as an internal reference. Melting points were determined by AS ONE 
instrument. X-ray data for the compound 6g was collected at room temperature using a Bruker 
Apex II KY CCD diffractometer with graphite monochromated MoKα radiation (λ=0.71073Å) 
with ω-scan method. Crystallographic data of 6g has been deposited with the Cambridge 
Crystallographic Data Centre as supplementary publication nos. CCDC 1484244 contains the 
supplementary crystallographic data for this paper. 
 
Experimental procedure for the synthesis of Ugi adducts (5a-5x): 
Pyrrole-2-carbaldehyde (1 mmol), corresponding aniline (1 mmol), substituted phenylglyoxylic 
acid (1.2 mmol) and isocyanide (1 mmol) were taken in 3 ml methanol. This mixture was stirred 
at room temperature for 20-60 min. During the stirring, white color precipitate formation was 
observed.  The precipitated Ugi adducts were filtered off and washed with ice cooled methanol 
(2 ml) to get pure products. No precipitate formation was observed for Ugi adducts 5c, 5d, 5m 
and 5q. These Ugi adducts were purified by column chromatography using 20% EtOAc/Hexane. 
In other cases, the volatiles were removed under reduced pressure. All the products were isolated 
in good yields ranging from 80-93%. 
Experimental procedure for the PTSA catalyzed synthesis of pyrrolo[2,3-c]pyridone 
derivatives (6a-6x): 
Ugi adduct (1 mmol, 5a-5x) was taken in 5ml methanol. To this PTSA (50mol %) was added and 
heated at 50oC for 1h. Methanol was removed under reduced pressure and water was added to 
the reaction mixture. Filtered the yellow solid precipitated and thoroughly washed with water to 
remove PTSA catalyst completely. The yellow solid was run flash column chromatography using 
5% DCM/MeOH. The yields are almost quantitative ranging from 91-98%.  
2-(2-{1-[N-(4-bromophenyl)-2-oxo-2-phenylacetamido]-2-tert-butylamino-2-oxoethyl}-1H-
pyrrol (5a) 
White solid, yield 90%; δH (500 MHz CDCl3) 1.38 (9 H, s), 5.51 (1 H, s), 5.79 (1 H, s), 6.14 (1 
H, m), 6.20 (1 H, m), 6.76 (1 H, m), 7.04 (2 H, m), 7.24 (2 H, m), 7.48 (2 H, t, J=6.4 Hz), 7.59 (1 
H, t, J=5.9 Hz), 7.96 (2 H, m), 9.44 (1 H, s); δC (125 MHz, CDCl3) 28.61, 51.91, 61.87, 108.21, 
111.50, 120.13, 123.02, 123.61, 128.93, 129.79, 130.96, 132.27, 133.14, 134.67, 138.04, 167.06, 
167.93, 189.84; HRMS-FAB(m/z) calcd for C24H24BrN3O3 ([M + H]+) 481.3698, found 
481.3690. 
2-(2-{1-[N-(4-chlorophenyl)-2-oxo-2-phenylacetamido]-2-tert-butylamino-2-oxoethyl}-1H-
pyrrol (5b) 
White solid, yield 88%; δH (500 MHz CDCl3) 1.39 (9 H, s), 5.54 (1 H, s), 5.82 (1 H, s), 6.13 (1 
H, m), 6.19 (1 H, m), 6.75 (1 H, m), 7.09 (4 H, m), 7.48 (2 H, t, J=6.2 Hz), 7.58 (1 H, m), 7.96 (2 
H, m), 9.45 (1 H, s); δC (125 MHz, DMSO-d6) 28.61, 51.91, 61.90, 108.30, 111.49, 120.12, 
123.63, 128.93, 129.28, 129.77, 130.65, 133.15, 134.65, 134.84, 137.52, 167.09, 168.00, 189.86; 
HRMS-FAB(m/z) calcd for C24H24ClN3O3 ([M + H]+) 436.9185, found 436.9193. 
2-(2-{1-[N-(4-methoxyphenyl)-2-oxo-2-phenylacetamido]-2-tert-butylamino-2-oxoethyl}-
1H-pyrrol (5c) 
White solid, yield 84%; δH (500 MHz CDCl3) 1.39 (9 H, s), 3.67 (3 H, s), 5.57 (1 H, s), 5.89 (1 
H, s), 6.12-6.14 (2 H, m), 6.59 (2 H, m), 6.73 (1 H, m), 7.03 (2 H, m), 7.45 (2 H, m), 7.56 (1 H, 
m), 7.96 (2 H, m), 9.46 (1 H, s); δC (125 MHz, CDCl3) 28.62, 51.79, 55.28, 61.65, 108.07, 
111.21, 114.10, 119.96, 124.03, 128.79, 129.69, 130.61, 131.24, 133.32, 134.38, 159.51, 167.34, 
168.29, 190.26; HRMS-FAB(m/z) calcd for C25H27N3O4 ([M + H]+) 432.4997, found 432.4988. 
2-(2-{1-[N-(4-methylphenyl)-2-oxo-2-phenylacetamido]-2-tert-butylamino-2-oxoethyl}-1H-
pyrrol (5d) 
White solid, yield 84%; δH (500 MHz CDCl3) 1.38 (9 H, s), 2.20 (3 H, s), 5.50 (1 H, s), 5.82 (1 
H, s), 6.13-6.20 (2 H, m), 6.75 (1 H, m), 6.91 (2 H, m), 7.01 (2 H, m), 7.43-7.47 (2 H, m), 7.55-
7.58 (1 H, m), 7.98 (2 H, m), 9.51 (1 H, s); δC (125 MHz, CDCl3) 21.95, 28.60, 51.88, 61.75, 
108.27, 111.44, 120.08, 122.95, 123.68, 129.67, 129.91, 130.76, 130.92, 132.25, 145.91, 167.13, 
168.11, 189.46; HRMS-FAB(m/z) calcd for C25H27N3O3 ([M + H]+) 416.5003, found 416.5013. 
2-(2-{1-[N-phenyl-2-oxo-2-phenylacetamido]-2-tert-butylamino-2-oxoethyl}-1H-pyrrol (5e) 
White solid, yield 80%; δH (500 MHz CDCl3) 1.39 (9 H, s), 5.54 (1 H, s), 5.83 (1 H, s), 6.13-6.20 
(2 H, m), 6.74 (1 H, m), 6.74-7.16 (5 H, m), 7.46 (2 H, m), 7.56 (1 H, m), 7.98 (2 H, m), 9.51 (1 
H, s); δC (125 MHz, CDCl3) 28.62, 51.82, 62.27, 119.97, 124.13, 128.74, 128.80, 129.09, 
129.12, 129.76, 133.32, 134.41, 139.16, 167.18, 168.18, 190.05; HRMS-FAB(m/z) calcd for 
C24H25N3O3 ([M + H]+) 402.4737, found 402.4744. 
2-(2-{1-[N-(2,4-dichlorophenyl)-2-oxo-2-phenylacetamido]-2-tert-butylamino-2-oxoethyl}-
1H-pyrrol (5f) 
White solid, yield 93%; δH (500 MHz CDCl3) 1.37 (9 H, s), 5.54 (1 H, s), 5.97 (1 H, m), 6.06 (1 
H, s), 6.68 (2 H, m), 7.00 (2 H, m), 7.11 (2 H, m), 7.46 (2 H, m), 7.57 (1 H, m), 7.97 (2 H, m); δC 
(125 MHz, CDCl3) 28.63, 52.03, 65.02, 115.83, 122.86, 124.81, 128.87, 129.88, 131.73, 131.82, 
132.87, 133.13, 134.60, 136.05, 156.54, 167.70, 168.14, 190.41; HRMS-FAB(m/z) calcd for 
C25H23Cl2N3O3 ([M + H]+) 471.3632, found 471.3625. 
2-(2-{1-[N-(4-bromophenyl)-2-oxo-2-(4-methoxyphenylacetamido)]-2-tert-butylamino-2-
oxoethyl}-1H-pyrrol (5g) 
White solid, yield 98%; δH (500 MHz CDCl3) 1.38 (9 H, s), 3.87 (3 H,s), 5.48 (1 H, s), 5.78 (1 H, 
s), 6.75 (1 H, m), 6.94 (2 H, m), 7.06 (2 H, m), 7.26 (2 H, m), 7.96 (2 H, d, J=8.05 Hz), 9.48 (1 
H, s); δC (125 MHz, CDCl3) 28.61, 51.87, 55.60,  62.17, 108.26, 111.45, 114.29, 120.12, 122.87, 
123.82, 126.29, 130.84, 132.24, 132.32, 138.43, 164.76, 167.15, 168.36, 188.46; HRMS-
FAB(m/z) calcd for C25H26BrN3O4 ([M + H]+) 511.3858, found 511.3866. 
2-(2-{1-[N-(4-bromophenyl)-2-oxo-2-(4-methlphenylacetamido)]-2-tert-butylamino-2-
oxoethyl}-1H-pyrrol (5h) 
White solid, yield 90%; δH (500 MHz CDCl3) 1.38 (9 H, s), 2.10 (3 H, s), 5.53 (1 H, s), 5.82 (1 
H, s), 6.13 (1 H, m), 6.19 (1 H, m), 6.74 (1 H, m), 7.03 (2 H, m), 7.26 (4 H, m), 7.86 (2 H, d, 
J=6.2 Hz), 9.46 (1 H, s); δC (125 MHz, CDCl3) 21.95, 25.60, 51.88, 61.76, 108.27, 111.44, 
120.08, 122.95, 123.68, 129.67, 129.91, 130.76, 130.92, 132.25, 145.91, 167.13, 168.11, 184.46;  
HRMS-FAB(m/z) calcd for C25H26BrN3O3 ([M + H]+) 495.3964, found 495.3972. 
2-(2-{1-[N-(4-bromophenyl)-2-oxo-2-(4-ethoxyphenylacetamido)]-2-tert-butylamino-2-
oxoethyl}-1H-pyrrol (5i) 
White solid, yield 92%; δH (500 MHz CDCl3) 1.38 (9 H, s), 1.45 (3 H, t), 4.07-4.11 (2 H, q), 5.53 
(1 H, s), 5.83 (1 H, s), 6.12-6.16 (2 H, m), 6.74 (1 H, m), 6.92 (2 H, m), 7.05 (2 H, m), 7.26 (2 H, 
m), 7.94 (2 H, m), 9.49 (1 H, s); δC (125 MHz, CDCl3) 14.62, 28.60, 51.86, 61.97, 63.95, 108.25, 
111.42, 114.70, 120.08, 122.86, 123.77, 126.06, 130.91, 132.20, 132.31, 138.30, 164.23, 167.19, 
168.39, 188.47; HRMS-FAB(m/z) calcd for C26H28BrN3O4 ([M + H]+) 525.4223, found 
525.4232. 
2-(2-{1-[N-(4-chlorophenyl)-2-oxo-2-(4-chlorophenylacetamido)]-2-tert-butylamino-2-
oxoethyl}-1H-pyrrol (5j) 
White solid, yield 86%; δH (500 MHz CDCl3) 1.37 (9 H, s), 5.47 (1 H, s), 5.74 (1 H, s), 6.12-6.17 
(2 H, m), 6.76 (1 H, m), 7.11 (4 H, m), 7.45 (2 H, m), 7.95 (2 H, m), 9.43 (1 H, s); δC (125 MHz, 
CDCl3) 28.59, 51.95, 62.55, 108.37, 111.63, 120.26, 123.53, 129.38, 129.41, 130.53, 131.16, 
131.52, 134.97, 137.58, 141.33, 166.90, 167.67, 188.70; HRMS-FAB(m/z) calcd for 
C24H23Cl2N3O3 ([M + H]+) 471.3632, found 471.3645. 
(2-{1-[N-(4-bromophenyl)-2-oxo-2-(4-chlorophenylacetamido)]-2-tert-butylamino-2-
oxoethyl}-1H-pyrrol (5k) 
White solid, yield 90%; δH (500 MHz CDCl3) 1.37 (9 H, s), 5.44 (1 H, s), 5.71 (1 H, s), 6.77 (1 
H, m), 7.06 (2 H, m), 7.28 (2 H, m), 7.46 (2 H, m), 7.96 (2 H, m), 9.42 (1 H, s); δC (125 MHz, 
CDCl3) 28.59, 51.95, 62.64, 108.38, 111.65, 120.29, 123.14, 123.60, 129.39, 130.77, 131.19, 
131.52, 132.44, 141.34, 166.87, 167.63, 188.65; HRMS-FAB(m/z) calcd for C24H23BrClN3O3 
([M + H]+) 515.8145, found 515.8156. 
2-{1-[N-(4-chlorophenyl)-2-oxo-2-(4-methylphenylacetamido)]-2-tert-butylamino-2-
oxoethyl}-1H-pyrrol (5l) 
White solid, yield 84%; δH (500 MHz CDCl3) 1.38 (9 H, s), 2.40 (3 H, s), 5.57 (1 H, s), 5.86 (1 
H, s), 6.12-6.18 (2 H, m), 6.76 (1 H, m), 7.08 (4 H, m), 7.25-7.26 (2 H, m), 7.86 (2 H, m), 9.46 
(1 H, s); δC (125 MHz, CDCl3) 21.92, 28.60, 51.88, 61.59, 108.27, 111.41, 120.03, 123.65, 
129.66, 129.89, 130.69, 130.76, 134.76, 137.49, 145.90, 167.17, 168.16, 189.52; HRMS-
FAB(m/z) calcd for C25H26ClN3O3 ([M + H]+) 450.9451, found 450.9442. 
2-{1-[N-(4-chlorophenyl)-2-oxo-2-phenylacetamido]-2-cyclohexylamino-2-oxoethyl}-1H-
pyrrol (5m) 
White solid, yield 82%; δH (500 MHz CDCl3) 1.11-1.94 (10 H, m), 3.87 (1 H, m), 5.58 (1 H, s), 
5.81 (1 H, d), 6.12-6.17 (2 H, m), 6.77 (1 H, m), 7.09-7.14 (4 H, m), 7.45-7.48 (2 H, m), 7.58 (1 
H, m), 7.99 (2 H, m), 9.51 (1 H, s); δC (125 MHz, CDCl3) 24.68, 25.42, 32.74, 48.97,  61.91, 
108.31, 111.65, 120.29, 123.52, 128.93, 129.33, 129.83, 130.63, 133.07, 134.68, 134.86, 137.66, 
166.82, 168.15, 189.97; HRMS-FAB(m/z) calcd for C26H26ClN3O3 ([M + H]+) 462.9558, found 
462.9548. 
2-{1-[N-(4-methylphenyl)-2-oxo-2-phenylacetamido]-2-cyclohexylamino-2-oxoethyl}-1H-
pyrrol (5n) 
White solid, yield 97%; δH (500 MHz CDCl3) 1.12-1.92 (10 H, m), 2.20 (3 H, s), 3.89 (1 H, m), 
5.49 (1 H, s), 5.74 (1 H, d), 6.13-6.19 (2 H, m), 6.78-6.94 (3 H, m), 7.05-7.07 (2 H, m), 7.44-7.54 
(2 H, m), 7.54-7.57 (1 H, m), 8.02 (2 H, m), 9.55 (1 H, s); δC (125 MHz, CDCl3) 21.06, 24.68, 
25.45, 32.76, 48.85,  62.48, 108.08, 111.45, 120.12, 124.17, 128.76, 128.78, 129.81, 129.86, 
133.29, 134.38, 136.78, 138.82, 166.95, 168.41, 190.21; HRMS-FAB(m/z) calcd for C27H29N3O3 
([M + H]+) 442.5376, found 442.5362. 
2-{1-[N-(4-methoxyphenyl)-2-oxo-2-methylphenylacetamido]-2-cyclohexylamino-2-
oxoethyl}-1H-pyrrol (5o) 
White solid, yield 90%; δH (500 MHz CDCl3) 1.12-1.67 (10 H, m), 3.67 (3 H, s), 3.87 (1 H, m), 
5.55 (1 H, s), 5.81 (1 H, s), 6.19 (2 H, m), 6.62 (2 H, m), 6.77 (1 H, m), 7.08 (2 H, m), 7.45 (2 H, 
m), 7.57 (1 H, m), 7.98 (2 H, m), 9.51 (1 H, s); δC (125 MHz, CDCl3) 24.69, 25.45, 32.78, 48.84, 
55.29, 62.05, 108.09, 111.40, 114.18, 120.00, 124.00, 128.80, 129.78, 130.52, 133.26, 134.40, 
159.52, 167.05, 168.47, 190.36; HRMS-FAB(m/z) calcd for C27H29N3O4 ([M + H]+) 458.5370, 
found 458.5360. 
2-{1-[N-(2,4-chlorophenyl)-2-oxo-2-phenylacetamido]-2-cyclohexylamino-2-oxoethyl}-1H-
pyrrol (5p) 
White solid, yield 89%; δH (500 MHz CDCl3) 1.14-1.92 (10 H, m), 3.86 (1 H, m), 5.54 (1 H, s), 
5.97 (1 H, m), 6.06 (1 H, d), 6.68-6.70 (2 H, m), 7.00-7.02 (2 H, m), 7.09-7.11 (2 H, m), 7.43-
7.46 (2 H, m), 7.55-7.58 (1 H, m), 7.97 (2 H, m), 9.46 (1 H, s); δC (125 MHz, CDCl3) 24.67, 
25.40, 32.72, 49.04,  65.02,  115.83, 122.86, 124.81, 128.87, 129.88, 131.73, 131.82, 132.87, 
133.13, 134.60, 136.05, 156.54, 167.70, 168.14, 190.41; HRMS-FAB(m/z) calcd for 
C26H25Cl2N3O3 ([M + H]+) 497.4005, found 497.4017. 
2-{1-[N-phenyl-2-oxo-2-phenylacetamido]-2-cyclohexylamino-2-oxoethyl}-1H-pyrrol (5q) 
White solid, yield 82%; δH (500 MHz CDCl3) 1.14-1.93 (10 H, m), 3.88 (1 H, m), 5.53 (1 H, s), 
5.77 (1 H, d), 6.13-6.19 (2 H, m), 6.78 (1 H, m), 7.13-7.20 (5 H, m), 7.43-7.46 (2 H, m), 7.54-
7.57 (1 H, m), 8.00 (2 H, m), 9.57 (1 H, s); δC (125 MHz, CDCl3) 24.68, 25.44, 32.75, 48.89,  
62.47, 108.13, 111.54, 120.19, 124.05, 128.77, 128.81, 129.04, 129.17, 129.83, 133.23, 134.45, 
139.44, 166.92, 168.34, 190.16; HRMS-FAB(m/z) calcd for C26H27N3O3 ([M + H]+) 428.5110, 
found 428.5122. 
2-{1-[N-(3-chlorophenyl)-2-oxo-2-phenylacetamido]-2-cyclohexylamino-2-oxoethyl}-1H-
pyrrol (5r) 
White solid, yield 84%; δH (500 MHz CDCl3) 1.12-1.92 (10 H, m), 3.87 (1 H, m), 5.48 (1 H, s), 
5.73 (1 H, d), 6.14-6.21 (2 H, m), 6.80 (1 H, m), 7.05-7.16 (3 H, m), 7.26 (1 H, m), 7.46-7.49 (2 
H, m), 7.57-7.59 (1 H, m), 8.02 (2 H, m), 9.54 (1 H, s); δC (125 MHz, CDCl3) 24.67, 25.42, 
32.73, 49.00,  62.66, 108.32, 111.80, 120.40, 123.63, 127.43, 128.93, 129.12, 129.21, 129.85, 
130.03, 133.09, 134.68, 140.69, 166.69, 168.21, 189.86; HRMS-FAB(m/z) calcd for 
C26H26ClN3O3 ([M + H]+) 462.9558, found 462.9568. 
2-{1-[N-(4-bromophenyl)-2-oxo-2-(4-chlorophenylacetamido)]-2-cyclohexylamino-2-
oxoethyl}-1H-pyrrol (5s) 
White solid, yield 90%; δH (500 MHz CDCl3) 1.35-1.91 (10 H, m), 3.85 (1 H, m), 5.48 (1 H, s), 
5.71 (1 H, d), 6.14-6.17 (2 H, m), 6.79 (1 H, m), 7.07-7.08 (2 H, m), 7.26-7.30 (2 H, m), 7.44-
7.46 (2 H, m), 7.98 (2 H, m), 9.47 (1 H, s); δC (125 MHz, CDCl3) 24.67, 25.40, 32.72, 49.04,  
62.53, 108.38, 111.82, 120.46, 123.18, 123.44, 129.41, 130.73, 131.23, 131.44, 132.50, 138.34, 
141.37, 167.75, 168.65, 188.74; HRMS-FAB(m/z) calcd for C26H25BrClN3O3 ([M + H]+) 
541.8158, found 541.8166. 
2-{1-[N-(4-chlorophenyl)-2-oxo-2-(4-chlorophenylacetamido)]-2-cyclohexylamino-2-
oxoethyl}-1H-pyrrol (5t) 
White solid, yield 86%; δH (500 MHz CDCl3) 1.11-1.91 (10 H, m), 3.87 (1 H, m), 5.49 (1 H, s), 
5.73 (1 H, d), 6.13-6.17 (2 H, m), 6.79 (1 H, m), 7.13 (4 H, m), 7.46 (2 H, m), 7.98 (2 H, m), 
9.47 (1 H, s); δC (125 MHz, CDCl3) 24.67, 25.40, 32.72, 49.03,  62.51, 108.30, 111.80, 120.43, 
123.45, 129.40, 129.48, 130.47, 131.22, 131.45, 135.01, 137.74, 141.36, 166.68, 167.81, 188.78; 
HRMS-FAB(m/z) calcd for C26H25Cl2N3O3 ([M + H]+) 497.4005, found 497.4020. 
2-{1-[N-(4-bromophenyl)-2-oxo-2-(4-methoxyphenylacetamido)]-2-cyclohexylamino-2-
oxoethyl}-1H-pyrrol (5u) 
White solid, yield 85%; δH (500 MHz CDCl3) 1.10-1.92 (10 H, m), 3.85 (1 H, m), 3.86 (3 H, s), 
5.51 (1 H, s), 5.76 (1 H, d), 6.13-6.16 (2 H, m), 6.78 (1 H, m), 6.93 (2 H, m), 7.09 (2 H, m), 7.25 
(2 H, m), 7.99 (2 H, m), 9.53 (1 H, s); δC (125 MHz, CDCl3) 24.68, 25.42, 32.72, 48.96,  55.58, 
62.21,  108.27, 111.62, 114.31, 120.30, 122.90, 123.69, 126.21, 130.80, 132.30, 132.39, 138.58, 
164.78, 166.90, 168.52, 188.57; HRMS-FAB(m/z) calcd for C27H28BrN3O4 ([M + H]+) 537.4330, 
found 537.4342. 
2-{1-[N-(4-bromophenyl)-2-oxo-2-(4-methylphenylacetamido)]-2-cyclohexylamino-2-
oxoethyl}-1H-pyrrol (5v) 
White solid, yield 85%; δH (500 MHz CDCl3) 1.16-1.91 (10 H, m), 2.40 (3 H, s), 3.86 (1 H, m), 
5.54 (1 H, s), 5.78 (1 H, d), 6.13-6.18 (2 H, m), 6.77 (1 H, m), 7.06 (2 H, m), 7.25 (4 H, m), 7.89 
(2 H, m), 9.50 (1 H, s); δC (125 MHz, CDCl3) 21.96, 24.68, 25.42, 32.72, 48.94,  61.89,  108.28, 
111.60, 120.27, 122.98, 123.61, 129.69, 129.97, 130.68, 130.86, 132.32, 138.36, 145.95, 166.84, 
168.27, 189.56; HRMS-FAB(m/z) calcd for C27H28BrN3O3 ([M + H]+) 521.4336, found 
521.4321. 
2-{1-[N-(4-chlorophenyl)-2-oxo-2-(4-methylphenylacetamido)]-2-cyclohexylamino-2-
oxoethyl}-1H-pyrrol (5w) 
White solid, yield 86%; δH (500 MHz CDCl3) 1.12-1.93 (10 H, m), 2.40 (3 H, s), 3.86 (1 H, m), 
5.57 (1 H, s), 5.82 (1 H, d), 6.12-6.17 (2 H, m), 6.76 (1 H, m), 7.13 (4 H, m), 7.25 (2 H, m), 7.89 
(2 H, m), 9.51 (1 H, s); δC (125 MHz, CDCl3) 21.96, 24.69, 25.43, 32.74, 48.94,  61.75,  108.27, 
111.58, 120.23, 123.58, 129.29, 129.68, 129.95, 130.62, 130.68, 134.78, 137.73, 145.93, 166.88, 
168.33, 189.62; HRMS-FAB(m/z) calcd for C27H28ClN3O3 ([M + H]+) 476.9823, found 
476.9837. 
2-{1-[N-(2-iodophenyl)-2-oxo-2-(4-methylphenylacetamido)]-2-cyclohexylamino-2-
oxoethyl}-1H-pyrrol (5x) 
White solid, yield 82%; δH (500 MHz CDCl3) 1.11-1.95 (10 H, m), 3.86 (1 H, m), 5.53 (1 H, s), 
5.76 (1 H, d), 6.13-6.18 (2 H, m), 6.78 (1 H, m), 7.06-7.08 (2 H, m), 7.25-7.27 (2 H, m), 7.45-
7.48 (2 H, m), 7.57-7.60 (1 H, m), 7.99 (2 H, m), 9.49 (1 H, s); δC (125 MHz, CDCl3) 24.68, 
25.42, 32.75, 48.97, 62.09, 108.32, 111.69, 120.34, 123.05, 123.56, 128.95, 129.86, 130.86, 
132.38, 133.07, 134.70, 138.34, 166.77, 168.11, 184.91; HRMS-FAB(m/z) calcd for 
C26H26IN3O3 ([M + H]+) 554.4075, found 554.4087. 
N-(tert-Butyl)-4-phenyl-6-(4-bromophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6a) 
Yellow solid, yield 96%, mp 177-181°C; δH (500 MHz DMSO-d6) 1.08 (9 H, s), 6.16 (1 H, s), 
7.27-7.68 (10 H, m), 8.34 (1 H, d, J= 8.01 Hz), 10.81 (1 H, s); δC (125 MHz, DMSO-d6) 28.24, 
51.62, 98.81, 113.53, 121.48, 121.92, 126.84, 128.17, 128.32, 130.09, 131.68, 131.71, 137.29, 
139.41, 139.82, 142.0, 157.65, 159.90; HRMS-FAB(m/z) calcd for C24H22BrN3O2 ([M + H]+) 
462.0915, found 462.0925. 
N-(tert-Butyl)-4-phenyl-6-(4-chlorophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6b) 
Yellow solid, yield 97%, mp 173-177°C; δH (500 MHz DMSO-d6) 1.07 (9 H, s), 6.16 (1 H, s), 
7.26-7.65 (10 H, m), 8.34 (1 H, s), 10.80 (1 H, s); δC (125 MHz, DMSO-d6) 28.24, 51.61, 98.79, 
121.88, 126.83, 128.16, 128.38, 128.74, 130.08, 131.35, 133.01, 137.31, 138.97, 139.86, 141.99, 
157.73, 159.91; HRMS-FAB(m/z) calcd for C24H22ClN3O2 ([M + H]+) 418.1435, found 
418.1445. 
N-(tert-Butyl)-4-phenyl-6-(4-methoxyphenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6c) 
Yellow solid, yield 98%, mp 162-164°C; δH (500 MHz DMSO-d6) 1.07 (9 H, s), 3.8 (3 H, s), 
6.25 (1 H, s), 7.02-7.81 (9 H, m), 8.35 (1 H, d, J= 8.01 Hz), 11.34 (1 H, s); δC (125 MHz, 
DMSO-d6) ; 28.33, 51.76, 55.93, 99.76, 114.06, 122.60, 125.97, 127.41, 128.54, 130.31, 130.35, 
131.97, 136.30, 138.12, 140.33, 141.80, 146.14, 159.38, 159.67; HRMS-FAB(m/z) calcd for 
C25H25N3O3 ([M + H]+) 414.1924, found 414.1935. 
N-(tert-butyl)-4-phenyl-6-(4-methylphenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6d) 
Yellow solid, yield 98%, mp 156-160°C; δH (500 MHz DMSO-d6) 1.05 (9 H, s), 2.38 (3 H, s), 
6.23 (1 H, s), 6.23-7.76 (10 H, m), 8.31 (1 H, d, J= 8.05 Hz), 11.16 (1 H, s); δC (125 MHz, 
DMSO-d6) 21.25, 28.27, 51.67, 99.43, 113.83, 122.41, 125.97, 127.21, 128.40, 128.53, 129.04, 
129.21, 129.72, 130.14, 136.66, 137.0, 138.10, 138.21, 140.08, 141.79, 156.02, 159.55; FAB: 
HRMS-FAB(m/z) calcd for C25H25N3O2 ([M + H]+) 398.1942, found 398.1950. 
N-(tert-Butyl)-4-phenyl-6-phenyl-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-carboxamide (6e) 
Yellow solid, yield 97%, mp 150-154°C; δH (500 MHz DMSO-d6) 1.04 (9 H, s), 6.30 (1 H, s), 
7.27-7.66 (11 H, m), 8.26 (1 H, d, J= 8.15 Hz), 10.94 (1 H, s); δC (125 MHz, DMSO-d6) ; 28.27, 
51.50, 98.69, 113.40, 121.78, 126.72, 128.12, 128.32, 128.67, 129.54, 130.09, 137.53, 139.49, 
140.12, 141.80, 157.90, 160.02; FAB: HRMS-FAB(m/z) calcd for C25H25N3O2 ([M + H]+) 
384.1838, found 384.1849. 
N-(tert-Butyl)-4-phenyl-6-(2,4-dichlorophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6f) 
Yellow solid, yield 97%, mp 182-184°C; δH (500 MHz DMSO-d6) 1.14 (9 H, s), 6.20 (1 H, s), 
7.26-7.79 (9 H, m), 8.43 (1 H, d, J= 8.10 Hz), 10.80 (1 H, s); δC (125 MHz, DMSO-d6) ; 28.24, 
51.82, 98.84, 113.53, 121.96, 126.91, 127.81, 127.94, 128.19, 129.49, 130.03, 132.35, 133.98, 
134.64, 137.09, 137.29, 140.21, 142.44, 157.17, 159.46; HRMS-FAB(m/z) calcd for 
C24H21ClN3O2 ([M + H]+) 353.3480, found 353.3488. 
N-(tert-Butyl)-4-(4-methoxyphenyl)-6-(4-bromophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-
7-carboxamide (6g) 
Yellow solid, yield 98%, mp 165-168°C; δH (500 MHz DMSO-d6) 1.08 (9 H, s), 3.79 (3 H, s), 
6.16 (1 H, s), 6.96-7.68 (9 H, m), 8.30 (1 H, d, J= 8.01 Hz), 10.72 (1 H, s); δC (125 MHz, 
DMSO-d6) 28.24, 51.58, 55.52, 98.84, 113.62, 121.38, 122.04, 127.55, 129.48, 131.21, 131.68, 
139.45, 139.54, 141.60, 157.80, 158.25, 160.04; HRMS-FAB(m/z) calcd for C25H24BrN3O3 ([M 
+ H]+) 493.3805, found 493.3816. 
N-(tert-Butyl)-4-(4-methylphenyl)-6-(4-bromophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6h) 
Yellow solid, yield 96% mp 190-194°C; δH (500 MHz DMSO-d6) 1.07 (9 H, s), 2.36 (3 H, s), 
6.26 (1 H, s), 7.20-7.67 (9 H, m), 8.31 (1 H, d, J= 8.01 Hz), 10.74 (1 H, s); δC (125 MHz, 
DMSO-d6) 21.37, 28.21, 51.59, 98.85, 113.68, 121.41, 121.96, 127.90, 128.75, 129.94, 131.68, 
134.34, 135.94, 139.50, 139.58, 141.83, 157.76, 159.99; HRMS-FAB(m/z) calcd for 
C25H24BrN3O3 ([M + H]+) 477.3805, found 477.3811. 
N-(tert-butyl)-4-(4-ethoxyphenyl)-6-(4-bromophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6i) 
Yellow solid, yield 97%, mp 163-167°C; δH (500 MHz DMSO-d6) 1.07 (9 H, s), 1.36 (2 H, t, J= 
6.95 Hz), 4.08 (2 H, q, J= 5.55 Hz), 6.16 (1 H, s), 6.94-7.69 (9 H, m), 8.30 (1 H, d, J= 8.05 Hz), 
10.71 (1 H, s); δC (125 MHz, DMSO-d6) 15.20, 28.24, 51.57, 98.86, 113.63, 114.08, 121.37, 
122.04, 127.51, 129.35, 131.21, 131.67, 139.42, 139.55, 141.57, 157.51, 157.80. 160.04; HRMS-
FAB(m/z) calcd for C25H24BrN3O3 ([M + H]+) 507.4071, found 507.4082. 
 
N-(tert-Butyl)-4-(4-chlorophenyl)-6-(4-chlorophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6j) 
Yellow solid, yield 97%, mp 239-242°C; δH (500 MHz DMSO-d6) 1.07 (9 H, s), 6.21 (1 H, s), 
7.39-7.69 (9 H, m), 8.39 (1 H, s), 10.94 (1 H, s); δC (125 MHz, DMSO-d6) 28.24, 51.68, 98.73, 
111.89, 121.87, 125.97, 128.23, 128.51, 128.99, 131.32, 131.80, 133.16, 136.11, 138.75, 140.24, 
141.92, 157.41, 159.72; HRMS-FAB(m/z) calcd for C24H21ClN3O2 ([M + H]+) 453.3480, found 
453.3492. 
N-(tert-butyl)-4-(4-chlorophenyl)-6-(4-bromophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6k) 
Yellow solid, yield 96%, mp 266-270°C; δH (500 MHz DMSO-d6) 1.07 (9 H, s), 6.20 (1 H, s), 
7.30-7.69 (9 H, m), 8.35 (1 H, d, J= 8.05 Hz), 10.90 (1 H, s); δC (125 MHz, DMSO-d6) 28.23, 
51.66, 98.66, 111.86, 121.58, 121.83, 128.21, 128.85, 131.07, 131.66, 131.74, 136.18, 139.25, 
140.20, 141.91, 157.51, 159.76; HRMS-FAB(m/z) calcd for C24H21BrClN3O2 ([M + H]+) 
497.7993, found 497.7999. 
N-(tert-butyl)-4-(4-methylphenyl)-6-(4-chlorophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6l) 
Yellow solid, yield 97%, mp 129-132°C; δH (500 MHz DMSO-d6) 1.07 (9 H, s), 2.51 (3 H, s), 
6.15 (1 H, s), 7.20-7.61 (9 H, m), 8.31 (1 H, d, J= 8.05 Hz), 10.74 (1 H, s); δC (125 MHz, 
DMSO-d6) 21.35, 28.24, 51.59, 98.85, 113.66, 121.94, 128.72, 128.75, 129.94, 131.35, 132.96, 
134.34, 135.95, 139.04, 139.59, 140.12, 141.83, 157.81, 159.99; HRMS-FAB(m/z) calcd for 
C25H24ClN3O2 ([M + H]+) 432.9298, found 432.9291. 
N-cyclohexyl-4-phenyl-6-(4-chlorophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-carboxamide 
(6m) 
Yellow solid, yield 96%, mp 190-194°C; δH (500 MHz DMSO-d6) 0.95-1.57 (10 H, m), 3.49 (1 
H, sex), 6.15 (1 H, d, J= 1.81 Hz), 7.26-7.65 (10 H, m), 8.65 (1 H, d, J= 8.05 Hz), 10.94 (1 H, s); 
δC (125 MHz, DMSO-d6) 24.59, 25.54, 31.80, 48.91, 98.73, 113.47, 121.89, 126.83, 128.03, 
128.16, 128.76, 130.08, 131.28, 133.11, 137.30, 138.77, 139.75, 141.88, 157.78, 159.63; HRMS-
FAB(m/z) calcd for C26H24ClN3O2 ([M + H]+) 444.9405, found 444.9413. 
N-cyclohexyl-4-phenyl-6-(4-methylphenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6n) 
Yellow solid, yield 97%, mp 169-173°C; δH (500 MHz DMSO-d6) 0.94-1.56 (10 H, m), 2.35 (3 
H, s), 3.47 (1 H, m), 6.15 (1 H, d, J= 1.81 Hz), 7.19-7.65 (9 H, m), 8.57 (1 H, d, J= 8.05 Hz), 
10.86 (1 H, s); δC (125 MHz, DMSO-d6) 21.19, 24.61, 25.56, 31.83, 48.22, 98.61, 113.30, 
121.80, 126.69, 128.11, 128.53, 129.10, 129.11, 130.09, 137.34, 137.59, 139.33, 141.61, 157.96, 
159.75; HRMS-FAB(m/z) calcd for C27H27N3O2 ([M + H]+) 424.5223, found 424.5231. 
 N-cyclohexyl-4-phenyl-6-(4-methoxyphenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6o) 
Yellow solid, yield 97%, mp 150-154°C; δH (500 MHz DMSO-d6) 0.95-1.59 (10 H, m), 3.47 (1 
H, m), 3.79 (3 H. s),  6.15 (1 H, d, J= 1.81 Hz), 6.99-7.65 (10 H, m), 8.58 (1 H, d, J= 8.05 Hz), 
10.98 (1 H, s); δC (125 MHz, DMSO-d6) 24.61, 25.56, 31.90, 48.22, 55.91, 98.70, 113.24, 
113.91, 121.79, 126.74, 128.14, 128.91, 130.09, 130.39, 132.53, 137.49, 139.58, 141.59, 157.85, 
159.72; HRMS-FAB(m/z) calcd for C27H27N3O3 ([M + H]+) 440.5217, found 440.5226. 
N-cyclohexyl-4-phenyl-6-(2,4-dichlorophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6p) 
Yellow solid, yield 98%, mp 139-142°C; δH (500 MHz DMSO-d6) 0.95-1.56 (10 H, m), 3.52 (1 
H, m), 6.25 (1 H, d, J= 1.81 Hz), 7.31-7.84 (9 H, m), 8.40 (1 H, d, J= 8.05 Hz), 10.98 (1 H, s); δC 
(125 MHz, DMSO-d6) 24.74, 25.57, 31.82, 48.63, 98.81, 122.09, 126.93, 127.46, 127.92, 
128.20, 129.55, 130.02, 132.44, 134.53, 137.04, 137.06, 140.19, 142.33, 157.20, 159.14; HRMS-
FAB(m/z) calcd for C26H23Cl2N3O2 ([M + H]+) 479.3854, found 479.3864. 
N-cyclohexyl-4-phenyl-6-phenyl-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-carboxamide (6q) 
Yellow solid, yield 96%, mp 199-202°C; δH (500 MHz DMSO-d6) 0.87-1.58 (10 H, m), 3.43 (1 
H, m), 6.15 (1 H, d, J= 1.81 Hz), 7.25-7.66 (11 H, m), 8.58 (1 H, d, J= 8.05 Hz), 10.90 (1 H, s); 
δC (125 MHz, DMSO-d6) 24.27, 25.54, 31.82, 48.27, 98.64, 113.35, 121.84, 126.74, 128.12, 
128.38, 128.42, 128.67, 129.44, 130.09, 137.50, 139.45, 139.89, 141.68, 157.89, 159.70; HRMS-
FAB(m/z) calcd for C26H25N3O2 ([M + H]+) 410.4957, found 410.4966. 
N-cyclohexyl-4-phenyl-6-(3-chlorophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-carboxamide 
(6r) 
Yellow solid, yield 96%, mp 199-203°C; δH (500 MHz DMSO-d6) 0.95-1.59 (10 H, m), 3.48 (1 
H, ,m), 6.16 (1 H, d, J= 1.81 Hz), 7.13-7.69 (10 H, m), 8.68 (1 H, d, J= 8.05 Hz), 10.97 (1 H, s); 
δC (125 MHz, DMSO-d6) 24.59, 25.55, 31.83, 48.32, 98.76, 113.55, 122.02, 126.87, 127.86, 
128.16, 128.30, 128.56, 129.60, 130.08, 130.39, 132.94, 137.23, 139.88, 141.13, 141.95, 157.74, 
159.57; HRMS-FAB(m/z) calcd for C26H24N3O2 ([M + H]+) 444.9405, found 444.9419. 
N-cyclohexyl-4-(4-chlorophenyl)-6-(4-bromophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6s) 
Yellow solid, yield 98%, mp 266-270°C; δH (500 MHz DMSO-d6) 0.95-1.59 (10 H, m), 3.49 (1 
H, m), 6.19 (1 H, d, J= 1.81 Hz), 7.28-7.69 (9 H, m), 8.68 (1 H, d, J= 8.05 Hz), 11.0 (1 H, s); δC 
(125 MHz, DMSO-d6) 24.56, 25.54, 31.78, 48.30, 98.59, 111.82, 121.69, 121.92, 128.19, 
128.50, 128.19, 128.50, 131.06, 131.58, 131.76, 131.78, 136.18, 139.06, 140.12, 141.79, 157.58, 
159.49; HRMS-FAB(m/z) calcd for C26H23BrClN3O2 ([M + H]+) 523.8365, found 523.8376. 
 
N-cyclohexyl-4-(4-chlorophenyl)-6-(4-chlorophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6t) 
Yellow solid, yield 98%, mp 272-276°C; δH (500 MHz DMSO-d6) 0.93-1.59 (10 H, m), 3.49 (1 
H, m), 6.19 (1 H, d, J= 1.81 Hz), 7.35-7.70 (9 H, m), 8.67 (1 H, d, J= 8.05 Hz), 11.04 (1 H, s); δC 
(125 MHz, DMSO-d6) 24.57, 25.53, 31.79, 48.32, 98.59, 111.81, 128.19, 128.58, 128.80, 
131.06, 131.25, 131.78, 133.21, 136.19, 138.61, 140.12, 141.79, 157.63, 159.49; HRMS-
FAB(m/z) calcd for C26H23Cl2N3O2 ([M + H]+) 479.3852, found 479.3864. 
N-cyclohexyl-4-(4-methoxyphenyl)-6-(4-bromophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6u) 
Yellow solid, yield 98%, mp 162-166°C; δH (500 MHz DMSO-d6) 0.95-1.56 (10 H, m), 3.40 (1 
H, m), 6.15 (1 H, d, J= 1.81 Hz), 6.96-7.66 (9 H, m), 8.61 (1 H, d, J= 8.05 Hz), 10.85 (1 H, s); δC 
(125 MHz, DMSO-d6) 24.60, 25.55, 31.80, 48.30, 98.80, 113.56, 113.62, 121.51, 129.45, 
131.21, 131.60, 131.70, 139.33, 139.42, 141.49, 157.81, 158.26, 159.73; HRMS-FAB(m/z) calcd 
for C27H26BrN3O3 ([M + H]+) 519.4178, found 519.4189. 
N-cyclohexyl-4-phenyl-6-(4-bromophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6v) 
Yellow solid, yield 97%, mp 180-184°C; δH (500 MHz DMSO-d6) 0.95-1.59 (10 H, m), 2.35 (3 
H, s), 3.47 (1 H, m), 6.23 (1 H, d, J= 1.81 Hz), 7.20-7.66 (9 H, m), 8.62 (1 H, d, J= 8.05 Hz), 
10.88 (1 H, s); δC (125 MHz, DMSO-d6) 21.35, 24.59, 25.55, 31.80, 48.29, 98.81, 113.67, 
121.54, 122.07, 127.55, 128.75, 129.93, 131.60, 131.71, 134.31, 135.97, 139.29, 141.72, 157.77, 
159.69; HRMS-FAB(m/z) calcd for C27H26BrN3O2 ([M + H]+) 503.4184, found 503.4193. 
N-cyclohexyl-4-(4-methylphenyl)-6-(4-chlorophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-
carboxamide (6w) 
Yellow solid, yield 98%, mp 166-170°C; δH (500 MHz DMSO-d6) 0.93-1.59 (10 H, m), 2.34 (3 
H, s), 3.48 (1 H, m), 6.14 (1 H, d, J= 1.81 Hz), 7.21-7.81 (8 H, m), 8.61 (1 H, d, J= 8.05 Hz), 
10.88 (1 H, s); δC (125 MHz, DMSO-d6) 21.35, 24.59, 25.54, 31.80, 48.30, 98.80, 113.65, 
122.05, 127.63, 128.74, 129.93, 131.27, 133.06, 134.32, 135.96, 138.83, 139.54, 141.71, 157.82, 
159.69; HRMS-FAB(m/z) calcd for C27H26ClN3O2 ([M + H]+) 458.9671, found 458.9681. 
N-(cyclohexyl)-4-phenyl-6-(2-iodophenyl)-5-oxo-1H-pyrrolo[2,3-c]pyridone-7-carboxamide 
(6x) 
Light yellow solid, yield 95%, mp 162-164°C; δH (500 MHz DMSO-d6) 0.91-1.80 (10 H, m), 
3.48 (1 H, m), 6.28 (1 H, d, J= 1.81 Hz), 7.12-7.95 (11 H, m), 8.67 (1 H, d, J= 8.01 Hz), 11.34 (1 
H, s); δC (125 MHz, DMSO-d6) ; 14.45, 21.26, 22.54, 48.58, 99.45, 114.19, 122.73, 125.97, 
127.31, 128.46, 128.57, 128.99, 130.03, 130.62, 136.51, 138.21, 139.34, 140.55, 142.04, 142.59, 
145.99, 155.49, 158.58; HRMS-FAB(m/z) calcd for C26H24IN3O2 ([M + H]+) 536.3912, found 
536.3924. 
N-(tert-Butyl)-4-(4-chlorophenyl)-6-(3-trifluoromethylphenyl)-5-oxo-1H-pyrrolo[2,3-
c]pyridone-7-carboxamide (6y) 
Yellow solid, yield 91%, mp 125-129°C; δH (500 MHz DMSO-d6) 0.94 (9 H, s), 6.14 (1 H, d, J= 
5 Hz), 7.37-7.74 (9 H, m), 8.26 (1 H, s), 10.85 (1 H, s); δC (125 MHz, DMSO-d6) ; 28.10, 51.59, 
98.70, 111.99, 121.96, 125.44, 126.47, 128.20, 128.62, 130.18, 131.13, 131.81, 133.84, 136.07, 
140.41, 140.59, 142.10, 157.67, 159.72; HRMS-FAB(m/z) calcd for C25H21ClF3N3O2 ([M + H]+) 
486.9012, found 486.9025. 
N-(cyclohexyl)-4-(4-trifluoromethylphenyl)-6-(4-bromophenyl)-5-oxo-1H-pyrrolo[2,3-
c]pyridone-7-carboxamide (6z) 
yellow solid, yield 87%, mp 145-149°C; δH (500 MHz DMSO-d6) 0.97-1.57 (10 H, m), 3.48 (1 
H, m), 6.25 (1 H, d, J= 1.81 Hz), 7.29-7.91 (9 H, m), 8.69 (1 H, d, J= 8.01 Hz), 11.13 (1 H, s); δC 
(125 MHz, DMSO-d6) ; 24.55, 25.52, 31.76, 48.32, 98.55, 111.22, 121.78, 121.84, 125.04, 
129.29, 130.58, 131.58, 131.81, 138.92, 140.54, 141.80, 142.03, 157.61, 159.38; HRMS-
FAB(m/z) calcd for C27H23BrF3N3O2 ([M + H]+) 557.3897, found 557.3888. 
4. Conclusions 
In conclusion we have demonstrated a mild, efficient and multicomponent protocol for the 
synthesis of novel pyrrolo[2,3-c]pyridone molecules. This method offers several advantages such 
as easy handling procedure, atom economy, short reaction time and huge molecular library can 
be synthesized by changing the substituents on four independent starting materials. In previous 
reported methods for pyrrolo[2,3-c]pyridones, expensive metal catalysts were used, where as in 
present method we used inexpensive PTSA catalyst. Considering these advantages we hope this 
methodology will be useful for medicinal chemists in drug discovery process. 
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Chapter 3 
One pot four component synthesis of novel 3-furyl coumarin 
derivatives  
Abstract: 
 Efficient and facile synthesis of 3-furyl coumarin derivatives has been achieved by reaction of 4-
chloro-3-formylcoumarin, secondary amines, dialkyl acetylenedicarboxylates and diversely 
substituted isocyanides using four component one pot reaction. All the products were isolated as 
yellow color fluorescent solids by column chromatography in quantitative yield and 
characterized with 1H NMR, C13 NMR, IR and FAB mass. 
1. Introduction 
Coumarin analogs have been considered as important class of heterocyclic compounds 
due to their significant applications as anticoagulant,1 antibacterial,2 antihypertensive,3 anti-
tubercular,4 antifungal,5 anticancer,6 HIV protease inhibition,7 Laser dyes and fluorescent 
properties.8 Similarly Furan ring is found in many pharmaceutically important substances like 
furanose form in carbohydrate, alkaloid pylocarpine and furacilin antibiotics. Coumarin analogs 
having both coumarin and furan heterocycles have gained the considerable attention of 
researchers due to their significant properties as anti-leishmania panamensis,9 dyes and 
fluorescent sensors.10 Coumarin analogs with furan heterocycle isolated from the plants origin 
such as microminutin, micromelin, psoralen, 8-methoxypsoralen have important properties in 
medicinal chemistry and bio photochemistry.11 It is well documented that by introducing a 
heteroaromatic substituent at 3-position the absorption and emission maxima of coumarin 
scaffold can be improved because of extended pi conjugation and consequently their 
optoelectronic properties can be improved.12 Based on this phenomena a variety of 3-heteroaryl 
coumarin derivatives have been synthesized and evaluated for their optoelectronic properties.13 
3-furyl coumarin falls under this class with extended pi conjugation. Thus the structural features 
and the wide spectrum of applications of furyl coumarin analogs have prompted the intense 
research by the chemists to develop novel, simple and efficient methods for their synthesis.  
There are many reports in literature for the synthesis of 3-furyl coumarin derivatives. 
These involve the condensation of substituted salicylaldehydes and furyl acetonitriles with 
subsequent hydrolysis of the resulting 2-imino coumarin intermediates in acidic medium,14 NBS 
bromination of  coumarin at 3-position followed by Suzuki-Miyaura cross-coupling reaction with 
furano boronic acids,15  condensation of  4-chloromethyl coumarins with salicylaldehydes in 
DMF in the presence of potassium carbonate16 and condensation of  phenol with 2-furyl acid 
chloride,17 followed by Fries rearrangement with benzoyl chloride under PTC conditions and 
condensation of coumarin chalcone hybrid with benzoyl chloride using TPP catalyst.18  
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Scheme 1.  Comparison of previous reports with our approach 
 
Most of the above protocols involved multistep synthesis, metal catalyst, high temperatures, 
limited substrate scope, tedious workup and long reaction times.  
A contemporary challenge in the world is environmental pollution. Multi component 
reactions are certainly one of the solutions for this problem due to the less release of chemical 
wastage compared with classical bicomponent reaction protocols and it is being considered as 
one of the green technology. Previously we have reported the efficient and convenient synthesis 
of novel 2-benzazepines and chromeno quinolines using green technology platforms.19 In this 
article, we have envisaged a four component one pot reaction using 4-chloro-3-formyl coumarin, 
secondary amines, dialkyl acetylene dicarboxylate, and isocyanides. The reaction proceeded 
smoothly and yielded the desired products in good to excellent yields (83 to 88%).  
2. Results and Discussion 
Initial attempts by us to successfully synthesize 3-furyl coumarin derivatives by three 
component reaction using 4-chloro-3-formyl coumarin, dimethyl acetylenedicarboxylate and 
tert-butyl isocyanide met with failure. Even when the reaction was conducted at reflux condition 
did not yield the desired compounds. Previous reports suggest that that 1,3-dipolar generated by 
the addition of electron deficient alkynes and isocyanides reacts with carbonyl functional group, 
results in furan derivatives.20 But, unfortunately in our case the reaction proceeded to generate a 
lot of unwanted products as observed by TLC, without the desired product. We envisaged that 
the problem could be because of chloride of 4-chloro-3-formyl coumarin, as the chloride is a 
labile group in 4-chloro-3-formyl coumarin molecule, which was known to undergo substitution 
reactions readily with nucleophiles, hence resulting in many spots on TLC in our case. To our 
satisfaction substitution of chloride with morpholine, followed by three component reaction 
generated the desired product (85%). Finally a four component reaction using 4-chloro-3-formyl 
coumarin, morpholine, t-butyl isocyanide and dimethyl acetylenedicarboxylate generated the 
desired product in good yield.  
Table 1. Screening of solvents for the synthesis of 3-furyl coumarin with 4-chloro-3-formyl 
coumarin, morpholine, dimethyl acetylenedicarboxylate and t-butyl isocyanide a 
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a carried out using 4-chloro-3-formyl coumarin (1 mmol), morpholine (2 mmol), dimethyl 
acetylenedicarboxylate (1 mmol), and  t-butyl isocyanide (1 mmol) under N2, b isolated yields,  
Entry Solvent T (0C) Time(h) 	
1 EtOH +) 8  NRc 
2 MeOH 80 8  NRc 
3 DMF 80 8   NR 
4 DCM 60 8    40 
5 CHCl3 60 8    40 
6 THF 80 8    50 
7 Toluene 80 3    80 
8  Benzene 80 2.5    85 
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c NR=no reaction. 
The order of addition of reactants was initially 4-chloro-3-formyl coumarin (1 eq) and 
morpholine (2 eq) taken and stirred at reflux for 2 min in benzene under N2. Subsequently 
dimethyl acetylenedicarboxylate and t-butyl isocyanide were added and refluxed for 2.5h. 
To choose the best solvent for conducting the reaction, we have optimized the reaction in 
different solvents under different conditions. No product formation was observed in polar 
solvents like EtOH, MeOH and DMF at room temperature as well as refluxed at 800C for 8h 
(Table 1, entries 1-3). Poor to moderate yields were observed in CHCl3, DCM and THF (Table 
1, entries 4-6).  Very good yields were observed in benzene and toluene (Table 1, entries 7-8). 
Among all the screened solvents benzene was found to be the more effective solvent with 85% 
yield with short reaction time. 
Under the optimized reaction conditions, a variety of secondary amines, dialkyl 
acetylenedicarboxylates and isocyanides were employed to evaluate the substrate scope of the 
reaction. All the reactions proceeded very smoothly under optimized reaction conditions. All the 
3-furanyl coumarins 1-14 were obtained in good yields. All the compounds reported in this paper 
are novel, characterized with 1H NMR, C13 NMR, IR and FAB mass. 
      When the reaction was performed using pentyl isocyanide, diethyl acetylenedicarboxylate, 4-
chloro-3-formyl coumarin and Morpholine (or) thiomorpholine, we have not observed usual 
reaction product in these cases. 
 
 
 
Table 2. Synthesis of novel 3-furyl coumarins 
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It was further reacted with another molecule of dipolar intermediate formed by the 
addition of pentyl isocyanide and diethylacetylene dicarboxylate (Scheme 3) formed ketenimine 
furyl coumarin analogs (products 13, 14) respectively and the yield of final product was 40%. 
When the reaction was conducted by using two equivalents of pentyl isocyanide, diethyl 
acetylenedicarboxylate as shown (Scheme 2), the yield of the final product ketenimine furyl 
coumarin was increased from 40 to 80%.  
This product formations were supported by literature reports, where secondary amines 
reacts with dipolar intermediate generated by the addition of electron withdrawing alkynes and 
isocyanides to form ketenimine products.21 
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Scheme 2a. Representation of the formation of products 13, 14 
 
 
 
a
 Reaction was performed using pentyl isocyanide (2 mmol), diethylacetylene dicarboxylate (2 
mmol), morpholine (or) thiomorpholine (2 mmol) and 4-chloro-3-formyl coumarin (1 mmol) 
We have not observed such kinds of products, when the reaction was attempted using t-
butyl isocyanide and cyclohexyl isocyanide. The reason could be because of steric hindrance of 
bulky t-butyl and cyclohexyl groups might be prevented the attack of second molecule of dipolar 
intermediate. Molecule 1 was crystallized in ethyl acetate solvent. From the SXRD data, it was 
concluded that molecule 1 was crystallized in monoclinic form along with ethyl acetate solvent 
molecule with p21/c space group. The ortep diagram of molecule is shown below (Fig. 1).  
 
Fig 1.ORTEP plot for the X-ray crystal structure of 1 at 50% probability 
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The synthesized compounds (1-14) were further evaluated for their optoelectronic properties. 
We have measured the UV-Vis absorption and fluorescence emissions of compounds 1-14 (Fig. 
2 and Fig. 3). The concentrations of 3-furyl coumarin derivatives were 2.0×10-4 mol/L for 
absorption in MeOH solvent. The results are summarized in Table 3. The shapes of absorption 
spectra of all the compounds are very similar to each other. The absorption spectra (Fig 2) have 
showed absorption maxima from 295 nm to 322 nm for all the compounds in methanol solvent. 
Table 3. UV-Visible absorption and fluorescence of compounds 1-14a 
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                         a The concentration of all the samples were 2.0×10-4mol/L in Methanol solvent 
 
  
 
 
 
 
            Figure 2. Absorption spectra of compounds 1-14 in MeOH solvent 
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                                   Figure 3. Emission spectra of compounds 1-14 in MeOH 
With the above results in hand, we would like to propose the plausible mechanism for the above 
reaction. The first step of the reaction was nucleophilic displacement of chloride group with 
secondary amine as shown in Scheme 3. 
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 Scheme 3. Plausible reaction mechanism for the formation of 3-furyl coumarin 
On the basis of well-established chemistry of isocyanides reactivity with dialkyl 
acetylenedicarboxylate, a zwitter ionic intermediate was expected. This zwitter ionic 
intermediate was added to carbonyl function of coumarin formed an intermediate, which finally 
undergoes rearrangement to form the final product.   
3. Experimental 
All reagents were purchased from TCI and Sigma Aldrich and used without further 
purification. All the products were characterized by 1H NMR, C13 NMR, IR, and Fab-Mass 
analysis. The NMR spectrum was recorded on a Bruker AMX-500 MHz instrument at room 
temperature in CDCl3 using TMS as an internal reference. Melting points were determined by 
AS ONE instrument. Absorption spectrum was measured by using JASCO V-550 UV/VIS 
Spectrophotometer and Fluorescence spectrum was measured by using Hitachi F-2500 
Fluorescence Spectrophotometer. X-ray data for the compound were collected at room 
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temperature using a Bruker Apex II KY CCD diffractometer with graphite monochromated 
MoKα radiation (λ=0.71073Å) with ω-scan method. Crystallographic data of 1 has been 
deposited with the Cambridge Crystallographic Data Centre as supplementary publication nos. 
CCDC 1424464 contains the supplementary crystallographic data for this paper. These data can 
be obtained free of charge at www.ccdc.cam.ac.uk/conts/retrieving.html [or from the Cambridge 
Crystallographic Data Centre (CCDC), 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44(0) 
1223 336 033; email: deposit@ccdc.cam.ac.uk]. 
General procedure for the synthesis of 3-furyl coumarin derivatives: 
A solution of 4-chloro-3-formyl coumarin (1 mmol) and secondary amine (2 mmol) were stirred 
at reflux for 2 min in benzene under N2. To this solution dialyl acetylenedicarboxylate (1 mmol), 
isocyanide (1 mmol) were added and refluxed at 800C for 2.5h. The volatiles were removed 
under reduced pressure. The crude reaction mixture was subjected to column chromatography 
using EtOAc/Hexane mobile phase. All the products were isolated as yellow color fluorescent 
solids in very good yields.   
4-morpholino-3-(2-N-t-butylamino-3,4-dimethylcarboxylate-5-furyl) 2H-1-Benzopyran-2-
one (1).  
Yellow color solid, mp 133-136 °C;  IR: νmax(KBr) 3288, 1732, 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.69 (1 H, J =1.2 Hz, dd) 7.54 (m, 1 H), 7.34 (1 H, J =1.0 
Hz, dd), 7.29 (m, 1 H), 7.02 (1 H, s), 3.85 (4 H, J =4.55 Hz, t), 3.78 (3 H, s), 3.75 (3 H, s), 3.25 
(4 H, m), 1.43 (9 H, s); δC (125 MHz, CDCl3) 165.4, 163.9, 162.7, 161.2, 159.5, 153.7, 138.1, 
132.2, 125.3, 123.2, 118.6, 117.8, 117.5, 102.7, 87.3, 67.0, 52.7, 52.0, 51.1, 30.1; LCMS: MH+, 
484. Anal. Calcd. For C25H28N2O8: C, 61.94; H, 5.86; N, 5.78. Found: C, 61.95; H, 5.83; N, 
5.80. 
4-morpholino-3-(2-N-cyclohexylamino-3,4-dimethylcarboxylate-5-furyl) 2H-1-Benzopyran-
2-one (2). 
Yellow color solid, mp 109-112 °C; IR; νmax(KBr) 3288, 1733, 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.69 (1 H, J =1.4 Hz, dd), 7.52 (1 H, m), 7.34 (1 H, J 
=1.0 Hz, dd), 7.28 (1 H, m), 6.78 (1 H, J =6.8 Hz, d ), 3.88 (4 H, J =4.5 Hz, t), 3.79  (3 H, s), 
3.78 (3 H, s), 3.19 (4 H, J =4.5 Hz, t), 2.05 (3 H, m), 1.76 (2 H, m), 1.61(1 H, m), 1.34 (3 H, m); 
δC (125 MHz, CDCl3) 165.2, 164.0, 162.1, 160.9, 159.1, 153.5, 137.6, 132.1, 125.1, 123.8, 
119.2, 117.8, 103.7, 86.5, 67.0, 52.1, 51.1, 51.0, 33.7, 33.7, 25.3, 24.6; LCMS: MH+, 510. Anal. 
Calcd. For C27H30N2O8: C, 63.50; H, 5.92; N, 5.51. Found: C, 63.50; H, 5.90; N, 5.53. 
4-thiomorpholino-3-(2-N-t-butylamino-3,4-dimethylcarboxylate-5-furyl) 2H-1-Benzopyran-
2-one (3). 
Yellow color solid, mp 107-109 °C; IR; νmax(KBr) 3288, 1732, 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.69 (1 H, J =1.2 Hz, dd), 7.52 (1 H, J =8 Hz, t), 7.28-
7.33 (2 H, J =1.0 Hz, dd), 7.05 (1 H, s), 3.78 (3 H, s), 3.75  (3 H, s), 3.39-3.48 (4 H, m), 2.77-
2.81 (4 H, m), 1.44 (9 H, s); δC (125 MHz, CDCl3) 165.6, 163.9, 163.0, 161.2, 160.6, 153.4, 
138.2, 132.4, 125.1, 123.7, 118.7, 118.1, 117.7, 103.6, 87.8, 53.2, 52.7, 51.8, 51.3, 28.0; LCMS: 
MH+, 500. Anal. Calcd. For C25H28N2O7S: C, 59.90; H, 5.69; N, 5.64. Found: C, 59.85; H, 5.71; 
N, 5.67.  
4-thiomorpholino-3-(2-N-cyclohexylamino-3,4-dimethylcarboxylate-5-furyl) 2H-1-
Benzopyran-2-one (4). 
Yellow color solid, mp 86-88 °C; IR; νmax(KBr) 3288, 1732, 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.82 (1 H, J =1.2 Hz, dd), 7.70 (1 H, J =6.8 Hz, d), 7.32 
(1 H, m), 7.25  (1 H, m), 6.81 (1 H, J =7.2 Hz,  d), 3.79 (3 H, s), 3.75  (3 H, s), 3.38-3.41 (4 H, 
m), 2.78-2.83 (4 H, m), 1.62 (1 H, m), 1.17-1.38  (10 H, m); δC (125 MHz, CDCl3) 162.2, 162.1, 
161.4, 160.7, 159.6, 153.4, 146.9, 134.1, 133.7, 132.0, 126.4, 126.1, 124.9, 119.2, 118.6, 117.9, 
105.3, 87.0, 60.9, 56.1, 52.9, 52.0, 51.1, 33.8, 28.7, 27.9, 25.3, 24.6; LCMS: MH+, 526. Anal. 
Calcd. For C27H30N2O7S: C, 61.50; H, 5.82; N, 5.32. Found: C, 61.55; H, 5.75; N, 5.34.  
4-piperidino-3-(2-N-t-butylamino-3,4-dimethylcarboxylate-5-furyl) 2H-1-Benzopyran-2-
one (5). 
Yellow color solid, mp 92-94 °C; IR; νmax(KBr) 3288, 1732, 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.72 (1 H, J =1.2 Hz, dd), 7.51 (1 H, J =6.9 Hz, t), 7.32 
(1 H, m), 7.26  (1 H, m), 7.0 (1 H, s), 3.78 (3 H, s), 3.73  (3 H, s), 3.08-3.22 (4 H, m), 1.73 (6 H, 
m), 1.43 (9 H, s); δC (125 MHz, CDCl3) 165.6, 164.2, 162.7, 161.6, 160.6, 153.6, 139.2, 131.9, 
125.5, 123.5, 118.2, 118.0, 118.0, 101.4, 87.2, 60.4, 52.6, 52.3, 51.9, 51.0, 30.0, 26.3, 24.0, 14.2; 
LCMS: MH+, 482. Anal. Calcd. For C26H30N2O7: C, 64.68; H, 6.29; N, 5.83. Found: C, 64.70; H, 
6.28; N, 5.82.  
4-piperidino-3-(2-N-cyclohexylamino-3,4-dimethylcarboxylate-5-furyl) 2H-1-Benzopyran-
2-one (6). 
Yellow color solid, mp 93-96 °C; IR; νmax(KBr) 3288, 1732, 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.71 (1 H, J =1.0 Hz, dd), 7.50 (1 H, J =6.5 Hz, t), 7.30 
(1 H, m), 7.26  (1 H, m), 6.76 (1 H, J =7.2 Hz, d), 3.79 (3 H, s), 3.75  (3 H, s), 3.11-3.15 (4 H, 
m), 2.01 (3 H, m), 1.59-1.73 (11 H, m), 1.33-1.36 (3 H, m) ; δC (125 MHz, CDCl3) 165.4, 164.1, 
162.1, 161.3, 160.3, 153.5, 138.8, 131.8, 125.3, 123.6, 118.5, 118.3, 117.6, 102.4, 86.4, 60.4, 
52.2, 51.9, 51.4, 51.3, 33.7, 26.2, 25.3, 24.6, 24.1, 14.2; LCMS: MH+, 508. Anal. Calcd. For 
C28H32N2O7: C, 66.10; H, 6.35; N, 5.53. Found: C, 66.11; H, 6.36; N, 5.51. 
4-N-dimethylamino-3-(2-N-t-butylamino-3,4-dimethylcarboxylate-5-furyl) 2H-1-
Benzopyran-2-one (7). 
Yellow color solid, mp 66-68 °C; IR; νmax(KBr) 3288, 1732, 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.88 (1 H, J =1.2 Hz, dd), 7.51 (1 H, J =6.4 Hz, t), 7.31 
(1 H, m), 7.24  (1 H, m), 6.97 (1 H, s), 3.77 (3 H, s), 3.74 (3 H, s), 2.98 (6 H, s), 1.42 (9 H, s); δC 
(125 MHz, CDCl3) 165.7, 164.1, 162.7, 161.3, 160.4, 153.6, 139.0, 132.0, 126.4, 123.5, 117.8, 
99.9, 86.9, 60.4, 52.6, 52.2, 51.1, 43.4, 29.8; LCMS: MH+, 441. Anal. Calcd. For C23H26N2O7: C, 
62.43; H, 5.90; N, 6.35. Found: C, 62.40; H, 5.95; N, 6.33. 
4-morpholino-3-(2-N-t-butylamino-3,4-diethylcarboxylate-5-furyl) 2H-1-Benzopyran-2-one 
(8). 
Yellow color solid, mp 102-105 °C; IR; νmax(KBr) 3288, 1732, 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.69 (1 H, J =1.0 Hz, dd), 7.54 (1 H, m), 7.34 (1 H, J 
=1.2 Hz, dd), 7.28 (1 H, m), 7.04 (1 H, s), 4.24 (4 H, m), 3.86  (4 H, J =4.5 Hz, q), 3.21-3.36 (4 
H, m), 1.43 (9 H, s), 1.32 (3 H, J =6.5 Hz, t), 1.26 (3 H, J =5.7 Hz, t); δC (125 MHz, CDCl3) 
165.1, 164.0, 162.7, 161.2, 160.6, 153.5, 137.8, 132.1, 125.1, 123.8, 119.0, 118.0, 117.8, 104.0, 
87.5, 60.7, 59.7, 53.1, 52.6, 30.5, 27.9, 14.1, 13.9; LCMS: MH+, 512. Anal. Calcd. For 
C27H32N2O8: C, 63.25; H, 6.29; N, 5.49. Found: C, 63.29; H, 6.27; N, 5.47. 
4-N-dimethylamino-3-(2-N-t-butylamino-3,4-diethylcarboxylate-5-furyl) 2H-1-Benzopyran-
2-one (9). 
Yellow color solid, mp 158-160 °C; IR; νmax(KBr) 3288, 1735, 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.77 (1 H, J =1.2 Hz, dd), 7.50 (1 H, J =6.5 Hz, t), 7.32 
(1 H, m), 7.25  (1 H, m), 6.98 (1 H, s), 4.24 (4 H, J =4.7 Hz, q), 2.98  (6 H, s), 1.42 (9 H, s), 
1.28-1.31 (3 H, J =6.2 Hz, t), 1.22-1.24 (3 H, s); δC (125 MHz, CDCl3) 165.4, 164.1, 162.8, 
161.6, 159.9, 153.8, 138.5, 131.9, 126.8, 123.4, 118.4, 117.8,  99.4, 87.4, 60.9, 59.4, 52.3, 43.4, 
29.4, 14.4, 14.3; LCMS: MH+, 469. Anal. Calcd. For C25H30N2O7: C, 63.78; H, 6.45; N, 5.97. 
Found: C, 63.82; H, 6.40; N, 5.98. 
4-thiomorpholino-3-(2-N-cyclohexylamino-3,4-diethylcarboxylate-5-furyl) 2H-1-
Benzopyran-2-one (10). 
Yellow color solid, mp 89-91 °C; IR; νmax(KBr) 3288, 1734, 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.69 (1 H, J =1.2 Hz, dd), 7.52 (1 H, J =6.4 Hz, t), 7.30 
(1 H, m), 7.28  (1 H, m), 6.80 (1 H, J =7.2 Hz, d), 4.24-4.26 (4 H, J =4.4 Hz, q), 3.37-3.40  (4 H, 
m), 2.78-2.82 (4 H, m), 1.74-1.78 (3 H, m), 1.59-1.61 (1 H, m), 1.25-1.36  (13 H, m); δC (125 
MHz, CDCl3) 165.1, 163.7, 162.0, 160.9, 159.9, 153.0, 137.0, 131.7, 124.9, 124.1, 119.8, 118.8, 
117.7, 105.4, 86.6, 60.6, 59.5, 52.7, 51.9, 34.7, 28.3,  24.7, 24.3, 14.6, 13.9; LCMS: MH+, 554. 
Anal. Calcd. For C29H34N2O7S: C, 62.80; H, 6.15; N, 5.08. Found: C, 62.78; H, 6.19; N, 5.06. 
4-piperidino-3-(2-N-t-butylamino-3,4-diethylcarboxylate-5-furyl) 2H-1-Benzopyran-2-one 
(11). 
Yellow color solid, mp 71-73 °C; IR; νmax(KBr) 3288, 1734, 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.71 (1 H, J =1.0 Hz, dd), 7.52 (1 H, J =6.6 Hz, t), 7.31 
(1 H, m), 7.30  (1 H, m), 7.01 (1 H, s), 4.18-4.23 (4 H, J =4.4 Hz, q), 3.08-3.29  (4 H, m), 1.64-
1.72 (6 H, m), 1.43 (9 H, s), 1.32 (3 H, J =6.2 Hz, t), 1.24 (3 H, J =5.7 Hz, t); δC (125 MHz, 
CDCl3) 165.2, 164.0, 162.7, 161.6, 160.6, 153.6, 138.7, 131.8, 125.5, 123.5, 118.4, 118.1, 101.6, 
87.3, 60.8, 59.3, 52.5, 52.2, 30.0, 26.3, 24.0, 14.2, 14.1; LCMS: MH+, 510. Anal. Calcd. For 
C28H34N2O7: C, 65.83; H, 6.75; N, 5.49. Found: C, 65.84; H, 6.70; N, 5.49. 
4-piperidino-3-(2-N-cyclohexylamino-3,4-diethylcarboxylate-5-furyl) 2H-1-Benzopyran-2-
one (12). 
Yellow color solid, mp 78-80 °C; IR; νmax(KBr) 3288, 1735, 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.71 (1 H, J =1.2 Hz, dd), 7.51 (1 H, J =6.6 Hz, t), 7.31 
(1 H, m), 7.26  (1 H, m), 6.77 (1 H, J =7.2 Hz, d), 4.20-4.26 (4 H, m), 3.14 (4 H, J =6.2 Hz, t), 
1.58-1.74 (11 H, m), 1.23-1.37 (12 H, m), 1.24 (3 H, J =5.7 Hz, t); δC (125 MHz, CDCl3) 165.0, 
163.9, 162.1, 161.4, 160.4, 153.4, 138.2, 131.8, 125.3, 123.6, 118.9, 118.3, 117.5, 102.4, 86.6, 
60.8, 59.6, 52.3, 52.2, 51.3, 33.7, 26.4, 25.3, 24.5, 24.1, 14.2, 14.1; LCMS: MH+, 536. Anal. 
Calcd. For C30H36N2O7: C, 67.10; H, 6.76; N, 5.27. Found: C, 67.13; H, 6.78; N, 5.22. 
4-morpholino-3-[2-N-pentyl-N-(4-pentylimino-1,2-diethyl-3-ketenimine dicarboxylate) -5-
furyl] 2 H-1-Benzopyran-2-one (13). 
Yellow color semi solid; IR; νmax(KBr) 2079, 1733,1728, 1667, 1658, 1618, 1418, 1240, 1041 
cm-1; δH (500 MHz CDCl3) 7.69 (1 H, J =1.2 Hz, dd), 7.52 (1 H, m), 7.33 (1 H, J =1.0 Hz, dd), 
7.28  (1 H, m), 6.73 (1 H, s), 4.11-4.29 (8 H, m), 3.86 (4 H, J =6.7 Hz, t), 3.06-3.19 (4 H, bm), 
1.52-1.65 (6 H, m), 1.17-1.37 (22 H, m), 0.88 (6 H, m); δC (125 MHz, CDCl3) 162,15, 162.11, 
161.69, 161.38, 160.70, 160.18, 153.86, 132.40, 131.15, 125.60, 125.33, 123.83, 123.72, 117.83, 
117.76, 117.16, 66.94, 62.22, 61.17, 60.91, 53.64, 51.68, 50.67, 49.83, 31.06, 29.73, 29.00, 
27.80, 22.58, 14.13, 14.04, 13.96, 13.91; LCMS: MH+, 793. Anal. Calcd. For C42H55N3O12: C, 
63.50; H, 6.98; N, 5.31. Found: C, 63.54; H, 6.94; N, 5.33. 

4-thiomorpholino-3-[2-N-pentyl-N-(4-pentylimino-1,2-diethyl-3-ketenimine dicarboxylate) -
5-furyl] 2 H-1-Benzopyran-2-one (14). 
Yellow color semi solid; IR; νmax(KBr) 2079, 1733, 1728, 1667, 1658, 1618, 1418, 1240, 1041 
cm-1; δH (500 MHz CDCl3) 7.69 (1 H, m), 7.54 (1 H, m), 7.32 (2 H, m), 6.78  (1 H, s), 4.11-4.29 
(8 H, m), 3.38 (4 H, bm), 2.80 (4 H, t), 1.53-1.65 (6 H, m), 1.17-1.37 (22 H, m), 0.89 (6 H, m); 
δC (125 MHz, CDCl3) 163.13, 162.15, 162.10, 161.69, 160.70, 160.18, 153.87, 132.39, 131.20, 
125.60, 123.72, 119.03, 117.76, 117.16, 66.94, 62.22, 61.27, 61.17, 60.90, 53.64, 51.68, 50.66, 
49.83, 31.05, 29.72, 28.98, 27.80, 27.45, 22.58, 22.48, 14.13, 14.06, 14.04, 13.95; LCMS: MH+, 
809. Anal. Calcd. For C42H55N3O11S: C, 62.30; H, 6.80; N, 5.20. Found: C, 62.27; H, 6.86; N, 
5.18. 
4. Conclusions 
In conclusion, we have reported a mild and efficient synthesis of 3-furyl coumarins via 
four component one pot reaction. The protocol afforded all the products as yellow color solids 
after column chromatography in good to excellent yields.  
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Chapter 4 
Synthesis of novel spiro[indole-2,2’-pyrroles] using isocyanide 
based multicomponent reaction 
Abstract: 
An efficient and facile method for the synthesis of novel spiro[indole-2,2'-pyrroles] from N-
methyl-3-isatin imines, t-butyl isocyanide and dialkyl acetylenedicarboxylate has been achieved 
by [3+2] cyclo addition reaction. All the products were purified by column chromatography as 
yellow solids and confirmed with 1H NMR, 13CNMR, FAB mass, IR. Compound 11 was further 
confirmed with X-ray analysis. 
1. Introduction 
  Isatin derivatives have several pharmacological and biological properties such as anti-
HIV,[1] anticancer,[2] anti-mycobacterial,[3] anti-inflammatory,[4] and anticonvulsant activities.[5] 
Isatin found to be a prevalent motif in several alkaloids,[6] drugs,[7] dyes,[8] pesticides and 
analytical reagents. Spiro compounds having both indole and pyrrole nucleus is found to be the 
key structural unit in many natural products such as Spirotriprostrain A, Spirotriprostrain B and 
Horsfiline, which were proven to have anticancer activity. [9] Because of the versatile reactivity of 
the isatin various methods have been developed for the synthesis of spiro [indole-pyrazoles] 
using multi component reactions.[10] However most of these methods were involved the C-3 
carbon of isatin in the formation of spiro heterocycle. Spiro compounds having dipyrrole namely 
Amathaspiramide A, Mytraginine psuedoindoxyl as shown below was proven to have prominent 
antiviral and anticancer properties.[11] Very few reports were there in the literature for the 
synthesis of spiro [indole-pyrazoles] bearing spiro carbon at C-2 position. [12] 
The reported method involved the multistep organic synthesis, used metal catalysts and 
tedious workup procedures. As a consequence and our passion towards the synthesis of novel 
heterocycles using multi component reactions, in this article we investigated an efficient and 
simple route for the synthesis of novel spiro [indole-2,2’-pyrazoles] bearing spiro carbon at C-2 
position. Previously we have reported the novel heterocycles like benzazepine, chromeno [4, 3-
b] quinolin-6-ones, chromeno-pyrimidine-N-oxides and chromeno [4, 3-b] pyridine-2, 5-diones. 
[13] 
 
 
 
                      Amathaspiramide A            Mytraginine psuedoindoxyl 
 
Herein we have demonstrated a novel three component [3+2] cyclo addition reaction for 
the synthesis of spiro [indole-pyrazoles] using C-2 carbon atom of isatin.  
2. Results and Discussions 
It was already reported in the literature N-methyl isatin reacts with zwitterionic 
intermediates generated by the addition of isocyanides to electron withdrawing alkynes, such as 
dialkyl acetylenedicarboxylate to form spirooxindoles.[14] We wanted to attempt the similar 
reaction using C-2 carbon of isatin. For this purpose we have protected the C2 carbon of isatin by 
means of ketal formation using ethylene glycol. Now, we have attempted a three component 
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reaction using the protected N-methyl isatin, dimethyl acetylenedicarboxylate and t-butyl 
isocyanide in benzene solvent. We have observed many spots in TLC. Hence, we have changed 
the protecting group to imine using different anilines. We have attempted a three component 
reaction by blocking the reactive C-3 carbonyl carbon atom of isatin by means of forming imine 
with 4-chloroanilines.  
Table 1. Effect of solvents for the synthesis of spiro[indole-2,2'-pyrroles] with N-methyl-3-(4-
chloro phenyl) isatin imine, dimethyl acetylenedicarboxylate and t-butyl isocyanide 
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To establish three component protocol, we have carried out a three component reaction using N-
methyl isatin-3-(4-chlorophenyl) imine, dimethyl acetylenedicarboxylate and t-Butyl isocyanide 
in toluene solvent under refluxing conditions for 24h (Table 1, Entry. 6). After column 
chromatography we have obtained the final product as a yellow solid with 60% yield. 
To optimize the reaction conditions we have screened the same reaction in different 
solvents and different conditions (Table 1). The choice of the solvent played profound effect on 
the reaction yields. No product formation was observed in polar solvents like MeOH, EtOH 
(Table 1, Entry. 1, 2). Halogenated solvents like CHCl3, DCM (Table 1, Entry. 3, 4) less yields 
were observed. Among all the solvents screened benzene (Table 1, Entry. 7) was found to be the 
best solvent with 70% yield with less reaction time.  
With the optimized reaction conditions in hand, we have demonstrated the reaction with 
different substituted N-methyl isatin imines and dialkyl acetylene dicarboxylates as shown in 
Table 2. We have attempted the reaction with various substituted N-methyl isatin imines, 
reaction went smoothly yielded 40-71%. 
 
Table 2.Synthesis of novel spiro [indole-2,2'-pyroles] scaffolds 
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Substrates like N-methyl isatin-3-(4-bromophenyl) imine, N-methyl isatin-3-(4-
chlorophenyl) imine, N-methyl isatin-3-(3-chlorophenyl) imine, N-methyl isatin-3-(phenyl) 
imine were reacted smoothly yielded the products as yellow solids (Table 2. Entry 1, 2, 4, 6, 7, 8, 
9, 11) with 60-71%. Substrates like N-methyl isatin-3-(2-chlorophenyl) imine, N-methyl isatin-
3-(2,4-dichlorophenyl) imine were less reactive yielded the products as yellow solids (Table 2. 
Entry 3, 5, 10, 12) with 40-45%. The reason for low yields of the reaction with substrates isatin-
3-(2-chlorophenyl) imine, N-methyl isatin-3-(2, 4-dichlorophenyl) imine could be steric 
hindrance of ortho substitution with t-butyl group. The reaction was also successful with pentyl 
isocyanide (Table 2. Entry 13). We had successfully regenerated the isatin carbonyl of final 
product 13(Scheme 1) using 2M aq.HCl in THF at room temperature.  
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Scheme 1. Hydrolysis of product 13 to retain isatin carbonyl 
All the products are novel characterized with 1H NMR, 13CNMR, FAB mass and IR. 
Structure of the product 11 was further confirmed by X-ray analysis of as shown in Figure 1. 
Good crystals were obtained for compound 11 in DCM solvent suitable for XRD. The molecule 
does not contain any hydrogen bonding from the X-ray analysis. The molecule was crystallized 
in a racemic form with two molecules in the unit cell and it has triclinic system with space group 
p-1. 
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On the basis of well-established chemistry of isocyanides I reactivity with dialkyl 
acetylenedicarboxylate II, initial step was the formation of zwitter ionic species as shown in 
scheme 1. This was reacted with activ
form a spiro Oxindole IV. This undergoes iminolactones
product spiro[indole-2,2'-pyrroles]. 
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3. Experimental 
All reagents were purchased from TCI and Sigma Aldrich and used without further 
purification. N-methyl isatin imines were synthesized according to the procedure reported in the 
literature. All the products were characterized by 1H NMR, C13 NMR, IR, and Fab-Mass 
analysis. The NMR spectra were recorded on a Bruker AMX-500 MHz instrument at room 
temperature in CDCl3 using TMS as an internal reference. Melting points were determined by 
AS ONE instrument. X-ray data for the compound were collected at room temperature using a 
Bruker Apex II KY CCD diffractometer with graphite monochromated MoKα radiation 
(λ=0.71073Å) with ω-scan method. Crystallographic data of 11 has been deposited with the 
Cambridge Crystallographic Data Centre as supplementary publication nos. CCDC 1037350 
contains the supplementary crystallographic data for this paper 
General procedure for the synthesis of spiro[indole-2,2'-pyrroles] (1-12): 
A solution of substituted N-methyl isatin imine (1 mmol), t-Butyl isocyanide (1 mmol) and 
dimethyl (or) diethyl acetylenedicarboxylate (1 mmol) in 10ml benzene were refluxed for 10-
14h. After completion of the reaction monitored by TLC, volatiles were removed under reduced 
pressure. The crude reaction mixture was subjected to column chromatography using (SiO2, 15% 
EtOAc/n-Hexane) yielded 40-71% as yellow color solids in most reactions and some cases as 
yellow color semi solids were obtained. 
General procedure for the synthesis of isatin imines: 
 A mixture of Isatin (1 mmol) and substituted aniline (1 mmol) were added into 10 ml of 
absolute ethanol containing a few drops of glacial acetic acid in a 50-ml round bottom flask. The 
reaction mixture was refluxed for 6h and recrystallized from ethanol to obtain pure products  
Synthesis of N-methyl isatin ketal: 
 A mixture of N-methyl isatin imine (1 mmol) and ethylene glycol (1.2 mmol) were taken 
in 10 ml benzene. To this catalytic amount of PTSA was added and refluxed for 10h. Benzene 
was removed and N-methyl isatin ketal was isolated as a white color solid using column 
chromatography. 
Procedure for the hydrolysis of product 13:  
 Compound 13 (1 mmol) was taken in 10 ml of 2M aq. HCl in THF and stirred at room 
temperature for 5h. The reaction mixture was basified with 20% NaHCO3 and extracted with 
EtOAC, product was isolated as yellow color solid using column chromatography using 20% 
EtOAC/Hexane. 
Spiro[indole-2,2'-pyrazole]-3-(4-chlorophenyl)imine-3',4'-dicarboxylicacid-1'-t-butyl-5'-one 
methyl ester  1.Yellow color solid, mp 163-166 °C; IR: νmax(KBr) 1728, 1667, 1658, 1618, 
1418, 1240, 1041 cm-1; δH (500 MHz CDCl3) 7.48 (2 H, m), 7.30 (1 H, m), 6.77 (2 H, m), 6.64 (1 
H, d), 6.61 (1 H, d), 6.47 (1 H, m), 3.90 (3 H, s), 3.63 (3 H, s), 2.82 (3 H, s), 1.49 (9 H, s); δC 
(125 MHz, CDCl3) 167.9, 165.5, 163.9, 161.8, 161.2 155.2, 149.7, 146.5, 135.3, 135.0, 131.1, 
126.4, 119.7, 118.6, 117.8, 116.9, 108.0, 88.1, 56.5, 53.0,  27.98; LCMS: MH+, 496.16. Anal. 
Calcd. For C26H26ClN3O5:C, 62.93; H, 5.24; Cl, 7.12; N, 8.45; O, 16.10. Found:C, 62.95; H, 
5.23; Cl, 7.14; N, 8.47; O, 16.13. 
Spiro[indole-2,2'-pyrazole]-3-(4-bromophenyl)imine-3',4'-dicarboxylicacid-1'-t-butyl-5'-
one methyl ester  2.Yellow color solid, mp 200-202 °C; IR: νmax(KBr) 1728, 1667, 1658, 1618, 
1418, 1240, 1041 cm-1; δH (500 MHz CDCl3) 7.32 (2 H, m), 7.29 (1 H, m), 6.81 (2 H, m), 6.63 (1 
H, d), 6.59 (1 H, d), 6.47 (1 H, m), 3.90 (3 H, s), 3.63 (3 H, s), 2.82 (3 H, s), 1.49 (9 H, s); δC 
(125 MHz CDCl3) 165.6, 163.7, 161.6, 161.2, 155.5, 149.2, 146.7, 135.0, 134.7, 129.3, 129.1, 
126.7, 119.4, 118.2, 117.8, 108.2, 88.5, 57.5, 52.88, 52.88, 27.7; LCMS: MH+, 541.17.Anal. 
Calcd. For C26H26ClN3O5: C, 57.77; H, 4.87; Br, 14.77; N, 7.80; O, 14.80. Found: C, 57.79; H, 
4.85; Br, 14.75; N, 7.82; O, 14.80. 
Spiro[indole-2,2'-pyrazole]-3-(2-chlorophenyl)imine-3',4'-dicarboxylicacid-1'-t-butyl-5'-one 
methyl ester  3.Yellow color solid, mp 148-152 °C; IR: νmax(KBr) 1728, 1667, 1658, 1618, 
1418, 1240, 1041 cm-1; δH (500 MHz CDCl3) 7.31 (1 H, dd), 7.25 (1 H, m), 7.17 (1 H, m), 7.03 
(1H, m), 6.79 (1 H, d), 6.58 (1 H, d), 6.39  (2 H, m), 3.84 (3 H, s), 3.52 (3 H, s), 2.77 (3 H, s), 
1.47 (9 H, s); δC (125 MHz CDCl3) 164.5, 163.7, 160.9, 159.8, 154.7, 146.7, 134.1, 129.17, 
126.7, 125.4, 123.9, 122.5, 118.1, 117.6, 116.9, 107.1, 87.4, 51.4, 50.3, 26.81; LCMS: MH+, 
496.16.Anal. Calcd. For C26H26ClN3O5: C, 62.93; H, 5.24; Cl, 7.12; N, 8.45; O, 16.10. Found: C, 
62.95; H, 5.23; Cl, 7.14; N, 8.47; O, 16.13. 
Spiro[indole-2,2'-pyrazole]-3-(3-chlorophenyl)imine-3',4'-dicarboxylicacid-1'-t-butyl-5'-one 
methyl ester (4).Yellow color solid, mp 195-197 °C; IR: νmax(KBr) 1728, 1667, 1658, 1618, 
1418, 1240, 1041 cm-1; δH (500 MHz CDCl3) 7.31 (2 H, t), 7.14 (1 H, m), 6.86 (1 H, t), 6.76 (1 
H, d), 6.62 (1 H, m), 6.58 (1 H, t), 6.47  (1 H, t), 3.90 (3 H, s), 3.64 (3 H, s), 2.83 (3 H, s), 1.50 (9 
H, s); δC (125 MHz CDCl3) 165.5, 163.9, 161.5, 161.2, 155.5, 151.9, 146.7, 135.1, 135.1, 130.6, 
126.8, 124.0, 118.1, 118.0, 117.8, 116.3, 108.2, 88.5, 57.5, 52.88, 52.8, 28.0; LCMS: MH+, 
496.16.Anal.Calcd. For C26H26ClN3O5: C, 62.93; H, 5.24; Cl, 7.12; N, 8.45; O, 16.10. Found: C, 
62.95; H, 5.23; Cl, 7.14; N, 8.47; O, 16.13. 
Spiro[indole-2,2'-pyrazole]-3-(2,4-dichlorophenyl)imine-3',4'-dicarboxylicacid-1'-t-butyl-
5'-one methyl ester  5. Yellow color solid, mp 146-148 °C; IR: νmax(KBr) 1728, 1667, 1658, 
1618, 1418, 1240, 1041 cm-1; δH (500 MHz CDCl3) 7.46 (1 H, m), 7.30 (1 H, m), 7.23 (1 H, m), 
6.80 (1H, d), 6.65 (1 H, d), 6.52 (2 H, m), 3.94 (3 H, s), 3.59 (3 H, s), 2.82 (3 H, s), 1.52 (9 H, s); 
δC (125 MHz CDCl3) 165.5, 163.9, 161.5, 161.2, 155.5, 151.9, 146.7, 135.1, 135.1, 130.6, 126.8, 
124.0, 118.12, 118.09, 117.8, 116.3, 116.1, 108.2, 88.5, 57.5, 53.0, 27.7; LCMS: MH+, 
529.12.Anal.Calcd. For C26H25Cl2N3O5: C, 58.84; H, 4.77; Cl, 13.38; N, 7.95; O, 15.06. Found: 
C, 58.86; H, 4.75; Cl, 13.39; N, 7.90; O, 15.08. 
Spiro[indole-2,2-'pyrazole]-3-(3-chlorophenyl)imine-3',4'-dicarboxylicacid-1'-t-butyl-5'-one 
ethyl ester  6. Yellow color solid, mp 138-140 °C; IR: νmax(KBr) 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.28-7.32 (2 H, m), 7.14 (1 H, m), 6.87 (1 H, t), 6.76 (1 
H, m), 6.63 (1H, d), 6.55 (1H, d), 6.47 (1H, m), 4.37 (2 H, q), 4.08 (2 H, q), 2.83 (3 H, s), 1.51 (9 
H, s), 1.37 (3 H, t), 0.99 (3 H, t); δC (125 MHz CDCl3) 165.7, 164.1, 161.2, 160.7, 155.6, 152.0, 
146.2, 135.3, 135.1, 130.7, 126.9, 124.0, 118.3, 118.1, 117.8, 116.1, 108.2, 88.4, 62.1, 57.4, 27.8, 
14.2, 13.5; LCMS: MH+, 524.01.Anal.Calcd. For C28H30ClN3O5: C, 64.18; H, 5.77; Cl, 6.77; N, 
8.02; O, 15.27. Found: C, 64.16; H, 5.75; Cl, 6.75; N, 8.04; O, 15.27. 
Spiro[indole-2,2-'pyrazole]-3-(4-chlorophenyl)imine-3',4'-dicarboxylicacid-1'-t-butyl-5'-one 
ethyl ester  7.Yellow color semi solid; IR: νmax(KBr) 1728, 1667, 1658, 1618, 1418, 1240, 1041 
cm-1; δH (500 MHz CDCl3) 7.34 (2 H, m), 7.29 (1 H, t), 6.82 (2 H, d), 6.62 (2 H, d), 6.46 (1 H, t), 
4.37 (2 H, q), 4.08 (2 H, q), 2.83 (3 H, s), 1.50 (9 H, s), 1.36 (3 H, t), 0.97 (3 H, t); δC (125 MHz 
CDCl3) 165.7, 163.9, 161.2, 160.7, 155.6, 149.3, 146.2, 135.3, 134.9, 129.6, 129.2, 126.7, 119.3, 
118.4, 117.6, 108.1, 88.5, 62.1, 57.4, 27.79, 14.2, 13.5; LCMS: MH+, 524.01.Anal.Calcd. For 
C28H30ClN3O5: C, 64.16; H, 5.79; Cl, 6.75; N, 8.04; O, 15.27. Found: C, 64.18; H, 5.77; Cl, 
6.77; N, 8.024 O, 15.25. 
Spiro[indole-2,2-'pyrazole]-3--(4-bromophenyl)imine-3',4'-dicarboxylicacid-1'-t-butyl-5'-
one ethyl ester  8.Yellow color semi solid; IR: νmax(KBr) 1728, 1667, 1658, 1618, 1418, 1240, 
1041 cm-1; δH (500 MHz CDCl3) 7.49 (2 H, t), 7.30 (1 H, t), 6.77 (2 H, m), 6.62 (1 H, d), 6.58 (1 
H, d), 6.47 (1 H, t), 4.38 (2 H, q), 4.08 (2 H, q), 2.82 (3 H, s), 1.50 (9 H, s), 1.37 (3 H, t), 0.98 (3 
H, t); δC (125 MHz CDCl3) 165.6, 163.8, 161.1, 160.7, 155.5, 149.7, 146.2, 135.2, 134.9, 132.5, 
126.7, 119.7, 118.3, 117.6, 116.8, 108.1, 88.4, 62.1, 28.0, 14.0, 13.5; LCMS: MH+, 
568.46.Anal.Calcd. For C28H30BrN3O5: C, 59.16; H, 5.32; Br, 14.06; N, 7.39; O, 14.07. Found: 
C, 59.14; H, 5.32; Br, 14.08; N, 7.37; O, 14.09. 
Spiro[indole-2,2-'pyrazole]-3-(4-methylphenyl)imine-3',4'-dicarboxylicacid-1'-t-butyl-5'-
one ethyl ester  9. Yellow color semi solid; IR: νmax(KBr) 1728, 1667, 1658, 1618, 1418, 1240, 
1041 cm-1; δH (500 MHz CDCl3) 7.24 (1 H, m), 7.18 (2 H, d), 6.77 (2 H, d), 6.59 (2 H, t), 6.42 (1 
H, t), 4.37 (2 H, q), 4.07 (2 H, q), 2.82 (3 H, s), 2.37 (3 H, s), 1.51 (9 H, s), 1.36 (3 H, t), 0.96 (3 
H, t); δC (125 MHz CDCl3) 165.7, 163.0, 161.30, 160.8, 155.3, 148.2, 135.2, 134.4, 133.4, 130.0, 
129.7, 126.8, 118.8, 117.6, 117.4, 115.2, 107.8, 88.5, 62.04, 57.3, 28.0, 14.2, 13.5; LCMS: MH+, 
503.59.Anal.Calcd. For C29H33N3O5: C, 69.17; H, 6.60; N, 8.34; O, 15.89. Found:C, 69.17; H, 
6.60; N, 8.34; O, 15.89. 
Spiro[indole-2,2-'pyrazole]-3-(o-chlorophenyl)imine-3',4'-dicarboxylicacid-1'-t-butyl-5'-one 
ethyl ester  10. Yellow color solid, mp 160-162 °C; IR: νmax(KBr) 1728, 1667, 1658, 1618, 
1418, 1240, 1041 cm-1; δH (500 MHz CDCl3) 7.30 (2 H, m), 7.18 (1 H, m), 6.83(1 H, t), 6.66 (1 
H, d), 6.53 (1 H, d), 6.55 (1 H, d), 6.47 (1 H, m), 4.36 (2 H, q), 4.08 (2 H, q), 2.82(3 H, s), 1.50 
(9 H, s), 1.37 (3 H, t), 0.99 (3 H, t); δC(125 MHz CDCl3) 165.7, 164.1, 161.1, 160.7, 155.6, 
152.1, 146.2, 135.2, 135.1, 135.1, 130.6, 126.9, 126.8, 124.0, 118.3, 118.1, 117.8, 116.1, 108.2, 
88.4, 62.13, 62.0, 57.4, 27.8, 14.2, 14.1; LCMS: MH+, 524.01.Anal.Calcd. For C28H30ClN3O5: C, 
64.16; H, 5.75; Cl, 6.77; N, 8.04; O, 15.25. Found: C, 64.16; H, 5.79; Cl, 6.77; N, 8.04; O, 
15.25. 
Spiro[indole-2,2-'pyrazole]-3-(phenyl)imine-3',4'-dicarboxylic acid-1'-t-butyl-5'-one ethyl 
ester  11. Yellow color solid, mp 184-186 °C; IR: νmax(KBr) 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.38 (2 H, t), 7.28 (1 H, m), 7.16 (1 H, t), 6.87 (2 H, m), 
6.61 (1 H, d), 6.49 (1 H, d), 6.41 (1 H, t), 4.37 (2 H, q), 4.07 (2 H, q), 2.83 (3 H, s), 1.52 (9 H, s), 
1.36 (3 H, t), 0.97 (3 H, t); δC (125 MHz CDCl3) 165.7, 163.2, 161.3, 160.8, 155.4, 150.9, 146.2, 
135.3, 134.6, 129.53, 126.8, 124.0, 118.7, 117.7, 117.5, 107.9, 88.5, 62.0, 57.4, 27.8, 14.2, 13.5; 
LCMS: MH+, 489.56.Anal.Calcd. For C28H31N3O5: C, 68.69; H, 6.36; N, 8.58; O, 16.36. Found: 
C, 68.69; H, 67.38; N, 8.58; O, 16.36 
Spiro[indole-2,2'-pyrazole]-3-(2,4--dichlorophenyl)imine-3',4'-dicarboxylicacid-1'-t-butyl-
5'-one ethyl ester  12. Yellow color semi solid ; IR: νmax(KBr) 1728, 1667, 1658, 1618, 1418, 
1240, 1041 cm-1; δH (500 MHz CDCl3) 7.46 (1 H, m), 7.34 (1 H, m), 7.23 (1 H, dd), 6.65 (2 H, 
d), 6.49-6.56 (2 H, m), 4.39 (2 H, q), 4.04 (2 H, q), 2.84 (3 H, s), 1.52 (9 H, s), 1.37 (3 H, t), 0.93 
(3 H, t); δC (125 MHz CDCl3) 165.6, 164.5, 161.45, 160.35, 156.0, 146.4, 135.4, 133.6, 129.9, 
129.4, 128.0, 126.4, 124.5, 120.1, 118.6, 118.0, 108.3, 88.4, 62.2, 57.5, 27.5, 14.1, 14.1; LCMS: 
MH+, 558.45.Anal.Calcd. For C28H29Cl2N3O5: C, 60.22; H, 5.23; Cl, 12.72; N, 7.50; O, 14.32. 
Found: C, 60.20; H, 5.23; Cl, 12.72; N, 7.48; O, 14.36. 
Spiro[indole-2,2'-pyrazole]-3-(4--chlorophenyl)imine-3',4'-dicarboxylicacid-1'-pentyl-5'-
one ethyl ester  13. Yellow color solid, mp 116-119 °C ; IR: νmax(KBr) 1728, 1667, 1658, 1618, 
1418, 1240, 1041 cm-1; δH (500 MHz CDCl3) 7.31-7.34 (3 H, m), 6.75-6.77 (2 H, m), 6.67 (1 H, 
d), 6.57 (1 H, m), 6.48 (1 H, t), 4.39 (2 H, q), 4.12 (2 H, q), 3.22 (2 H, t), 2.75 (3 H, s), 1.60 (4 H, 
m), 1.39 (3 H, t), 1.26 (2 H, m), 1.04 (3 H, t), 0.83 (3 H, t); δC (125 MHz CDCl3) 165.0, 163.6, 
161.4, 160.2, 156.9, 149.1, 143.9, 137.8, 135.1, 129.6, 129.3, 126.7, 119.5, 117.7, 107.9, 87.3, 
62.3, 62.0, 40.6, 29.2, 27.9, 22.2, 14.1, 13.9, 13.6; LCMS: MH+, 558.45.Anal.Calcd. For 
C28H29Cl2N3O5: C, 60.22; H, 5.23; Cl, 12.72; N, 7.50; O, 14.32. Found: C, 60.20; H, 5.23; Cl, 
12.72; N, 7.48; O, 14.36. LCMS: MH+, 537. Anal.Calcd. For C29H32ClN3O5: C, 64.72; H, 5.99; 
Cl, 6.61; N, 7.81; O, 14.87. Found: C, 64.74; H, 5.99; Cl, 6.59; N, 7.79; O, 14.89 
Analytical data for Hydrolyzed compound: 
Spiro[indole-2,2'-pyrazole]-3-one-3',4'-dicarboxylicacid-1'-pentyl-5'-one ethyl ester. Yellow 
color solid, mp 236-240 °C ; IR: νmax(KBr) 1740, 1736, 1660, 1618, 1240, 1041 cm-1; δH (500 
MHz CDCl3) 7.59 (1 H, t), 7.64 (1 H, dd), 6.82-6.87 (2 H, m), 4.42 (2 H, q), 4.04 (2 H, q), 3.22 
(2 H, t), 2.75 (3 H, s),  m), 1.44 (2 H, m), 1.38 (3 H, t), 1.22 (4 H, m), 0.97 (3 H, t); δC (125 MHz 
CDCl3) 192.38, 165.06, 161.20, 159.61, 145.78, 140.40, 138.88, 125.59, 119.9, 118.79, 108.79, 
85.61, 62.42, 62.14, 40.72, 28.97, 28.27, 27.75, 22.07, 14.05, 13.81, 13.34; LCMS: MH+, 428. 
Anal.Calcd. For C23H26N2O6: C, 64.45; H, 6.59; N, 6.56; O, 22.40. Found: C, 64.47; H, 6.61; N, 
6.54; O, 22.38  
4. Conclusion 
An efficient and environmental friendly method for the synthesis of novel spiro[indole-
2,2'-pyrroles] using readily available starting materials is reported. The notable advantages of 
this protocol are operational simplicity, easily available starting materials, available diversity of 
each component, catalyst free and easy work procedure employed. We believed in this protocol 
will help in developing novel spiro heterocyclic compounds using C-2 carbon atom of isatin. 
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Chapter 5 
Catalyst free, water mediated synthesis of 2,3-disubstituted 
imidazo[1,2-a]pyridines derivatives using three-component 
reaction and evaluation of their photophysical properties 
Abstract: 
New coumarin derivatives having imidazo[1,2-a]pyridine heterocycle moiety were 
synthesized by the condensation of 4-morpholino-3-formyl coumarin, diversely substituted 2-
amino pyridine and isocyanides under catalyst free, water mediated reaction conditions. All the 
products were characterized by using IR, NMR (1H and 13C) spectroscopy and HRMS 
spectrometry. Product 4b was further characterized with X-ray diffraction analysis. All the 
products have showed UV-Visible absorbance in between 234 nm to 248 nm and emissions were 
observed in between 412 nm to 544 nm.  
1.  Introduction 
  In the contemporary world one of the major problems that the world is facing is 
environmental pollution. Pharmaceutical industry is one of the polluter causing environmental 
pollution. So, the major challenge for the pharmaceutical industries is to keep focus on 
developing sustainable, environmental benign chemical methods for the synthesis of 
pharmaceutically active compounds. In this context, water mediated and catalyst free protocols 
for the synthesis valuable heterocyclic compounds have been attracting great attention because 
such methodologies reduces the generation of organic waste, water is abundant, inexpensive, non 
toxic and environmental benign solvent.[1] 
 Imidazo[1,2-a]pyridines have been valuable to organic and medicinal chemists due to the 
interesting structure and numerous applications in pharmaceutical Industry [1-12]. The molecules 
possessing imidazo[1,2-a]pyridine core structure have been used as  anticancer [13-15], anti-
inflammatory [16-17],  antibacterial [18-19], antiprotozonal [20-22] and antiviral [23-25] agents. 
They have been found in drug molecules such as Minodronic acid (I), Zolpidem (II), Zolmidine 
(III) and Olprinone (IV). 
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Figure 1. Examples of bioactive drugs containing imidazo[1,2-a]pyridine structure 
  As part of our research objectives to develop environmental benign methods for the 
synthesis of valuable heterocyclic compounds, herein, we would like to report the synthesis and 
photophysical properties of novel coumarin derivatives having imidazo[1,2-a]pyridine 
heterocycle moiety with extended pi conjugation. Previously we reported the synthesis of novel 
benzazepinone derivatives using water as a reaction solvent [26]. There were already few 
methods available for the synthesis of coumarin derivatives having imidazo[1,2-a]pyridine 
heterocycle moiety (Scheme 1).  
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Scheme 1.  Comparison of previous reports with our approach 
These methods involved the reaction of bromoacetyl coumarin with 2-aminopyridines 
[27], condensation between 2-aminopyridines and 3-(2-(4-bromophenyl)-2-oxoethyl)-2H-
chromen-2-one [28], multicomponent reaction of arylglyoxals, cyclic 1,3-dicarbonyls and 2-
aminopyridine [29]. However, these methods have disadvantages like poor solubility of products 
in organic solvents, limited substrate scope and harsh reaction conditions were used. 
2. Results and discussions 
Groebke-Blackburn-Bienayme reaction is the most familier, widely used general reaction 
for the generation of imidazo[1,2-a]pyridine derivatives [30-32], it involved one-pot 
condensations of aldehydes, isonitriles, and 2-aminopyridines.  
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Table 1. Condensations of 4-morpholino-3-formyl coumarin, 2-amino pyridine and t-butyl 
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aReaction conditions: all the reactants were taken 1mmol each and reaction was performed under 
reflux in a given solvent, except entries 6, 1 equivalent catalyst was used    
bIsolated yields 
cNo catalyst 
 
In the present study, we have performed the Groebke-Blackburn-Bienayme reaction to 
synthesize the novel coumarin analogs using 4-morpholino-3-formyl coumarin as aldehyde 
component. Initially, to choose best reaction conditions to conduct the reaction, we have 
performed a three component condensation reaction using 4-morpholino-3-formyl coumarin, 2-
amino pyridine and t-Butyl isocyanide under different reaction conditions (Table 1). The choice 
of the solvent and catalyst showed significant effect on the rate of the reaction. Low yields were 
observed under basic reaction conditions irrespective of solvent choice (Table 1, Entry. 1-3). On 
the other hand, when the reaction was performed in EtOH and Benzene solvents using PTSA 
catalyst, moderate yields were observed (Table 1, Entry. 4, 5). 
The reaction proceeded smoothly in water solvent using 30% PTSA catalyst, 85% of the 
product 4a formation was observed (Table 1, Entry. 6). When the same reaction was conducted 
in water without PTSA catalyst and refluxed for 10h, 91% of the product 4a formation was 
observed (Table 1, Entry.7). From the optimization reaction conditions, water was selected as a 
best solvent to conduct the reaction. With the optimization conditions in hand, further to explore 
the substrate scope of the reaction, a wide variety of 2-aminopyridines, isocyanides were reacted 
under optimized reaction conditions keeping the 4-morpholino-3-formyl coumarin constant. The 
results are summarized in Table 2. Various 2-aminopyridines possessing –Me, -oMe, -I, -Br, -Cl 
in different positions were reacted under the optimized reaction conditions and in all these cases 
moderate to excellent yield were observed (50-93%). Isocyanides possessing t-butyl, cyclohexyl, 
and n-pentyl groups were reacted in combination with various 2-aminopyridines. From the 
experimental results, it was concluded that electronic factors showed significant effect on the rate 
of this reaction. When the reaction was performed with 2-aminopyridine having –Cl, -Br, -I 
groups, less yields were obtained compare to unsubstituted 2-aminopyridines or its derivatives 
having electron donating groups. Very good yields were obtained with unsubstituted 2-
aminopyridines and 2-aminopyridines with electron releasing groups –Me, -OMe. Substituents 
on isocyanides have no effect on the rate of the reaction.  
Table 2.Synthesis of coumarin derivatives having imidazo[1,2-a]pyridine (4a-4q) 
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Scheme 2. Plausible reaction mechanism for the synthesis of imidazo[1,2-a]pyridine 
The synthesized compounds (4a-4q) were further evaluated for their optoelectronic 
properties. We have measured the UV-Vis absorption and fluorescence emissions of compounds 
4a-4q in MeOH solvent. The concentrations of coumarin derivatives were 2.0×10-4 mol/L for 
absorption in MeOH solvent. The results are summarized in Table 3. All the compounds have 
showed UV-Visible absorbance in between 234 nm to 248 nm and emissions were observed in 
between 412 nm to 544 nm. 
 
 
 
 
Table 3. UV-Visible absorption and fluorescence of compounds 4a-4q 
Compound λabs/nm λex/nm λem/nm 
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a The concentration of all the samples were 2.0×10-4mol/L in Methanol solvent 
3. Experimental 
All reagents were purchased from TCI and Sigma Aldrich and used without further 
purification. N-methyl isatin imines were synthesized according to the procedure reported in the 
literature. All the products were characterized by 1H NMR, C13 NMR, IR, and Fab-Mass 
analysis. The NMR spectra were recorded on a Bruker AMX-500 MHz instrument at room 
temperature in CDCl3 using TMS as an internal reference. Melting points were determined by 
AS ONE instrument. X-ray data for the compound were collected at room temperature using a 
Bruker Apex II KY CCD diffractometer with graphite monochromated MoKα radiation 
(λ=0.71073Å) with ω-scan method. Crystallographic data of 4b has been deposited with the 
Cambridge Crystallographic Data Centre as supplementary publication nos. CCDC 1440029 
contains the supplementary crystallographic data for this paper. 
General procedure for the synthesis of coumarin derivatives having imidazo[1,2-a]pyridine 
(4a-4q): 
A solution of 4-morpholino-3-formyl coumarin (1 mmol), corresponding 2-
aminopyridine (1 mmol) and isocyanide (1 mmol) were taken in 15 ml water solvent and 
refluxed for 10h. The reaction mixture was cooled to room temperature. Filtered off the solid 
products precipetated and passed through filter column using 50% EtOAc/Hexane mobile phase. 
All the products were isolated good yields ranging from 60-93%. 
4-Hydroxy-3-(3-(N-t-butylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-one (4a). 
White color solid, mp 249-253°C; IR: νmax(KBr) 3095, 2966, 1733, 1586, 1521, 1462 cm-1; δH 
(500 MHz DMSO-d6) 1.01 (9 H, s), 5.24 (1 H, s), 7.26-7.28 (2 H, m), 7.36-7.38 (1 H, m), 7.52-
7.55 (1 H, m), 7.75-7.78 (1 H, m), 7.85 (1 H, m), 8.01 (1 H, J= 1.35 Hz, dd), 8.77 (1 H, J= 6.75 
Hz, d); δC (125 MHz, CDCl3) 29.6, 56.8, 88.4, 111.7, 116.1, 116.4, 122.5, 123.3, 124.8, 124.9, 
125.6, 127.8, 131.1, 131.9, 136.2, 153.8, 163.4, 173.5; HRMS-FAB(m/z) calcd for C20H19N3O3 
([M + H]+) 348.3833, found 348.3845. 
4-Hydroxy-3-(3-(N-cyclohexylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-one (4b). 
Yellow color solid, mp 222-225°C; IR: νmax(KBr) 3164, 2927, 1734, 1586, 1521, 1462 cm-1; δH 
(500 MHz CDCl3) 1.11-1.30 (5 H, m), 1.53-1.84 (5 H, m), 2.68 (1 H, sex), 4.72 (1 H, d), 7.12-
7.14 (1 H, m), 7.26-7.31 (2 H, m), 7.44-7.47 (1 H, m), 7.50-7.54 (1 H, , m), 7.59-7.61 (1 H, m), 
8.11-8.13 (1 H, J=1.35 Hz, dd), 8.30 (1 H, J=6.7 Hz, d); δC (125 MHz, CDCl3) 25.2, 25.6, 33.8, 
56.6, 56.7, 90.9, 112.3, 114.5, 116.4, 120.4, 123.4, 123.5, 124.9, 125.7, 127.5, 131.8, 134.6, 
135.8, 153.4, 163.7, 173.5; HRMS-FAB(m/z) calcd for C22H21N3O3 ([M + H]+) 374.4206, found 
374.4214. 
4-Hydroxy-3-(3-(N-pentylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-one (4c). 
Yellow color solid, mp 168-172°C; IR: νmax(KBr) 3165, 2928, 1730, 1658, 1630 cm-1; δH (500 
MHz CDCl3) 0.83-0.87 (3 H, J=7.15 Hz, t), 1.24-1.37 (4 H, m), 1.54-1.60 (2 H, J=7.1Hz, quin), 
2.87 (2 H, J=6.65 Hz, t), 6.03 (1 H, s), 7.10-7.13 (1 H, J=6.8 Hz, t), 7.23-7.29 (2 H, m), 7.41-
7.43 (1 H, m), 7.48-7.51 (1 H, m), 7.70 (1 H, J=8.45 Hz, d), 8.09 (1 H, J=1.45 Hz, dd), 8.27 (1 
H, J=6.8 Hz, d); δC (125 MHz, CDCl3) 14.01, 22.5, 29.2, 30.1, 48.4, 90.6, 112.5, 114.6, 116.3, 
120.6, 122.9, 123.4, 125, 126.3, 127.2, 127.6, 131.8, 134.8, 153.4, 163.9, 173.6; HRMS-
FAB(m/z) calcd for C21H21N3O3 ([M + H]+) 362.4099, found 362.4087. 
 4-Hydroxy-3-(8-methyl-3-(N-t-butylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-one 
(4d). White color solid, mp 250-254°C; IR: νmax(KBr) 3247, 2956, 1729, 1657, 1594 cm-1; δH 
(500 MHz CDCl3) 1.11 (9 H, s), 2.62 (3 H, s), 5.41 (1 H, s), 6.99-7.02 (1 H, J=6.85 Hz, t), 7.25-
7.32 (3 H, m), 7.51-7.52 (1 H, m), 8.11-8.13 (1 H, J=1.5 Hz, dd), 8.45-8.47 (1 H, J=6.6 Hz, d); 
δC (125 MHz, CDCl3) 15.8, 29.5, 57.3, 91.1, 114.1, 116.5, 120.3, 121.9, 122.4, 123.5, 124.7, 
124.8, 127.6, 130.3, 131.9, 135.5, 153.5, 163.3, 173.8; HRMS-FAB(m/z) calcd for C21H21N3O3 
([M + H]+) 362.4099, found 362.4086. 
4-Hydroxy-3-(8-methyl-3-(N-cyclohexylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-
one (4e). Yellow color solid, mp 176-178°C; IR: νmax(KBr) 3279, 2929, 1730, 1647, 1604 cm-1; 
δH (500 MHz CDCl3) 1.11-1.31 (5 H, m), 1.54-1.84 (5 H, m), 2.63 (3 H, s),  2.68 (1 H, m), 6.02 
(1 H, J=8.5 Hz, d), 7.01-7.04 (1 H, J=3.2 Hz, t), 7.22-7.32 (3 H, m), 7.51-7.54 (1 H, m), 8.11-
8.14 (2 H, m); δC (125 MHz, CDCl3) 15.9, 25.3, 25.6, 33.7, 56.6, 91.4, 114.4, 116.5, 120.0, 
121.3, 122.5, 123.5, 124.6, 125.8, 126.6, 127.6, 131.8, 134.8, 153.3, 163.3, 173.3; HRMS-
FAB(m/z) calcd for C23H23N3O3 ([M + H]+) 388.4471, found 389.4486. 
4-Hydroxy-3-(8-methyl-3-(N-pentylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-one 
(4f). Yellow color solid, mp 102-104°C; IR: νmax(KBr) 3297, 2946, 1717, 1669, 1540 cm-1; δH 
(500 MHz CDCl3) 0.85-0.88 (3 H, J=7.25 Hz, t), 1.24-1.37 (4 H, m), 1.56-1.62 (2 H, J=7.1 Hz, 
quin), 2.60 (3 H, s), 2.85-2.89 (2 H, J=3.65 Hz, q), 6.20-6.22 (1 H, J=6.8 Hz, t), 6.99-7.02 (1 H, 
J=6.85 Hz, t), 7.19-7.20 (1 H, m), 7.23-7.30 (2 H, m), 7.49-7.53 (1 H, m), 8.08-8.10 (2 H, J=1.15 
Hz, dd); δC (125 MHz, CDCl3) 14.1, 15.9, 22.6, 29.2, 30.1, 48.6, 91.4, 114.5, 116.4, 119.9, 
120.8, 122.6, 123.5, 124.6, 126.5, 127.1, 131.8, 134.7, 153.2, 163.3, 173.1; HRMS-FAB(m/z) 
calcd for C22H23N3O3 ([M + H]+) 376.4364, found 376.4375. 
4-Hydroxy-3-(6-methoxy-3-(N-t-butylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-
one (4g). White color solid, mp 188-190°C; IR: νmax(KBr) 3276, 2966, 1734, 1652, 1528 cm-1; 
δH (500 MHz CDCl3) 1.08 (9 H, s), 3.86 (3 H, s), 5.26 (1 H, s), 6.77 (1 H, m), 7.00 (1 H, s), 7.21-
7.24 (2 H, m), 7.46-7.49 (1 H, m), 8.12 (1 H, J=1.45 Hz, dd), 8.39 (1 H, J=7.4 Hz, d); δC (125 
MHz, CDCl3) 29.5, 56.3, 56.8, 90.1, 90.8, 108.6, 116.2, 121.9, 123.1, 124.0, 125.1, 125.3, 127.3, 
131.4, 137.7, 153.6, 161.4, 174.6; HRMS-FAB(m/z) calcd for C21H21N3O4 ([M + H]+) 378.4093, 
found 378.4080. 
4-Hydroxy-3-(6-methoxy-3-(N-cyclohexylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-
2-one (4h). Yellow color solid, mp 192-194°C; IR: νmax(KBr) 3259, 2927, 2853, 1734, 1663, 
1595 cm-1; δH (500 MHz CDCl3) 1.10-1.25 (5 H, m), 1.52-1.83 (5 H, m), 2.62 (1 H, m),  3.85 (3 
H, s), 5.72 (1 H, J=8.45 Hz, d), 6.78 (1 H, J=7.1 Hz, d), 7.00 (1 H, s), 7.21-7.26 (2 H, m), 7.46-
7.49 (1 H, m), 8.12 (1 H, J=7.8 Hz, d); δC (125 MHz, CDCl3) 25.2, 25.6, 33.7, 56.3, 57.4, 89.9, 
91.00, 109.1, 116.2, 121.6, 123.2, 124.9, 125.1, 125.2, 131.4, 136.8, 153.4, 160.9, 164.2, 174.2; 
HRMS-FAB(m/z) calcd for C21H21N3O4 ([M + H]+) 404.4465, found 404.4482. 
4-Hydroxy-3-(6-methoxy-3-(N-pentylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-one 
(4i). Yellow color solid, mp 130-134°C; IR: νmax(KBr) 3262, 1919, 1730, 1663, 1595 cm-1; δH 
(500 MHz CDCl3) 0.81-0.84 (3 H, J=7.15 Hz, t), 1.23-1.35 (4 H, m), 1.51-1.57 (2 H, J=7.4 Hz, 
quin), 2.80-2.84 (2 H, J=6.85 Hz, q), 3.84 (3 H, s), 5.87 (1 H, J=7.1 Hz, t), 6.76-6.78 (1 H, J=2.3 
Hz, dd), 7.02 (1 H, s), 7.21-7.26 (2 H, m), 7.45-7.49 (1 H, m), 8.07-8.11 (2 H, m); δC (125 MHz, 
CDCl3) 13.9, 22.5, 29.2, 29.9, 48.9, 56.2, 89.7, 91.1, 109.1, 116.1, 121.6, 123.2, 123.8, 124.0, 
125.2, 126.1, 131.4, 136.8, 153.4, 160.9, 164.3, 174.2 ; HRMS-FAB(m/z) calcd for C22H23N3O4 
([M + H]+) 392.4358, found 392.4371. 
4-Hydroxy-3-(6-methyl-3-(N-t-butylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-one 
(4j). White color solid, mp 232-235°C; IR: νmax(KBr) 3202, 2973, 1730, 1635, 1607 cm-1; δH 
(500 MHz CDCl3) 1.11 (9 H, s), 2.44 (3 H, s), 5.36 (1 H, s), 7.22-7.29 (2 H, m), 7.33-7.34 (1 H, 
J=7.55 Hz, d), 7.60-7.61 (1 H, J=9 Hz, d), 8.10-8.11 (1 H, J=1.5 Hz, dd), 8.39 (1 H, s); δC (125 
MHz, CDCl3) 18.4, 29.5, 57.2, 90.4, 111.1, 116.4, 121.4, 122.2, 123.2, 124.5, 124.6, 125.2, 
129.5, 131.6, 131.7, 134.3, 153.7, 164.2, 174.7; HRMS-FAB(m/z) calcd for C22H23N3O4 ([M + 
H]+) 362.4099, found 362.4070. 
4-Hydroxy-3-(6-methyl-3-(N-cyclohexylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-
one (4k). Yellow color solid, mp 242-244°C; IR: νmax(KBr) 3212, 2932, 2854, 1717, 1684, 1653 
cm-1; δH (500 MHz CDCl3) 1.13-1.29 (5 H, m), 1.53-1.84 (5 H, m), 2.45 (3 H, s),  2.67 (1 H, m), 
5.89 (1 H, J=8.5 Hz, d), 7.24-7.25 (1 H, m), 7.28-7.31 (2 H, m), 7.48-7.50 (1 H, m), 7.54-7.56 (1 
H, J=9.1 Hz, d), 8.06 (1 H, s), 8.10-8.11 (1 H, J=1.45 Hz, dd); δC (125 MHz, CDCl3) 18.5, 25.6, 
33.7, 56.7, 90.4, 111.4, 116.4, 120.9, 121.1, 123.3, 124.8, 125.0, 125.4, 127.4, 130.7, 131.7, 
133.3, 153.4, 163.6, 174.1; HRMS-FAB(m/z) calcd for C23H23N3O3 ([M + H]+) 388.4471, found 
388.4487. 
4-Hydroxy-3-(6-methyl-3-(N-pentylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-one 
(4l). Yellow color solid, mp 102-104°C; IR: νmax(KBr) 3297, 2946, 1717, 1669, 1540 cm-1; δH 
(500 MHz CDCl3) 0.84-0.86 (3 H, J=7.1 Hz, t), 1.24-1.37 (4 H, m), 1.56-1.62 (2 H, J=7.1Hz, 
quin), 2.45 (3 H, s), 2.85-2.86 (2 H, J= 3.44 Hz, q), 6.11 (1 H, J=6.2 Hz, t), 7.24-7.30 (3 H, m), 
7.48-7.54 (2 H, m), 8.04 (1 H, s), 8.09-8.11 (1 H, J=1.35 Hz, dd); δC (125 MHz, CDCl3) 14.0, 
14.2, 18.4, 22.5, 29.2, 30.0, 48.3, 90.4, 111.5, 116.3, 120.8, 123.4, 124.9, 125.0, 126.4, 126.6, 
130.5, 131.7, 133.1, 153.4, 163.9, 174.1; HRMS-FAB(m/z) calcd for C22H23N3O3 ([M + H]+) 
376.4364, found 376.4390. 
4-Hydroxy-3-(6-bromo-3-(N-t-butylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-one 
(4m). Yellow solid, mp 232-235°C; IR: νmax(KBr) 3179, 2966, 1734, 1684, 1644 cm-1; δH (500 
MHz CDCl3) 1.12 (9 H, s), 5.21 (1 H, s), 7.29-7.33 (2 H, m), 7.39-7.41 (1 H, m), 7.48-7.50 (1 H, 
m), 7.54-7.56 (1 H, m), 8.07-8.08 (1 H, m), 8.62 (1 H, s); δC (125 MHz, CDCl3) 29.5, 57.3, 99.6, 
114.4, 116.5, 123.8, 124.3, 124.5, 125.6, 130.0, 132.1, 132.3, 136.0, 140.1, 148.7, 153.2, 157.0, 
168.4; HRMS-FAB(m/z) calcd for C20H18BrN3O3 ([M + H]+) 427.2793, found 427.2768. 
4-Hydroxy-3-(6-bromo-3-(N-cyclohexylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-
one (4n). Yellow color solid, mp 216-218°C; IR: νmax(KBr) 3177, 3095, 2966, 1734, 1684, 1652 
cm-1; δH (500 MHz CDCl3) 1.15-1.30 (5 H, m), 1.56-1.82 (5 H, m), 2.69 (1 H, J=7.2 Hz, t), 5.80 
(1 H, d), 7.29-7.37 (5 H, m), 7.42-7.44 (1 H, m), 8.29 (1 H, s); δC (125 MHz, CDCl3) 25.2, 25.6, 
33.8, 56.6, 94.0, 108.3, 114.8, 116.4, 118.1, 123.1, 123.9, 124.4, 126.7, 129.1, 129.7, 132.2, 
135.1, 153.0, 162.5, 169.8 ; HRMS-FAB(m/z) calcd for C22H20BrN3O3 ([M + H]+) 453.3166, 
found 453.3182. 
4-Hydroxy-3-(6-chloro-3-(N-t-butylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-one 
(4o). White color solid, mp 232-235°C; IR: νmax(KBr) 3180, 3097, 2964, 1730, 1684, 1652 cm-1; 
δH (500 MHz CDCl3) 1.10 (9 H, s), 5.21 (1 H, s), 7.26-7.33 (3 H, m), 7.53-7.57 (2 H, m), 8.07-
8.08 (1 H, J=1.45 Hz, dd), 8.52 (1 H, s); δC (125 MHz, CDCl3) 29.7, 57.2, 93.6, 114.0, 116.4, 
121.9, 122.1, 123.7, 124.6, 125.8, 128.2, 132.1, 132.2, 135.5, 153.2, 163.0, 170.7; HRMS-
FAB(m/z) calcd for C20H18ClN3O3 ([M + H]+) 382.8280, found 382.8299. 
4-Hydroxy-3-(6-chloro-3-(N-cyclohexylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-
one (4p). White color solid, mp 205-207°C; IR: νmax(KBr) 3256, 2926, 1715, 1656 cm-1; δH (500 
MHz CDCl3) 1.14-1.29 (5 H, m), 1.55-1.82 (5 H, m), 2.67 (1 H, m), 5.79-5.81 (1 H, J=7.4 Hz, 
d), 7.25-7.32 (3 H, m), 7.50-7.55 (2 H, m), 8.05-8.06 (1 H, J=1.05 Hz, dd), 8.19 (1 H, s); δC (125 
MHz, CDCl3) 25.2, 25.6, 33.8, 56.6, 93.6, 114.4, 116.4, 118.4, 120.9, 122.1, 123.8, 124.5, 126.8, 
127.2, 129.7, 132.2, 134.8, 153.1, 162.7, 170.2; HRMS-FAB(m/z) calcd for C22H20ClN3O3 ([M + 
H]+) 408.8653, found 408.8677. 
4-Hydroxy-3-(6-iodo-3-(N-t-butylamino)imidazo[1,2-a]pyridin-2-yl)-2H-chromen-2-one 
(4q). Yellow color solid, mp 232-234°C; IR: νmax(KBr) 3177, 3095, 2966, 1734, 1684, 1652 cm-
1; δH (500 MHz CDCl3) 1.10 (9 H, s), 5.22 (1 H, s), 7.30-7.35 (4 H, m), 7.50-7.57 (2 H, m), 8.74 
(1 H, s); δC (125 MHz, CDCl3) 28.5, 56.2, 109.8, 113.3, 115.4, 122.7, 123.6, 124.1, 128.1, 131.1, 
133.9, 134.6, 144.3, 152.2, 152.7, 156.3, 162.3, 170.1; HRMS-FAB(m/z) calcd for C20H18IN3O3 
([M + H]+) 474.2798, found 474.2766. 
 
4. Conclusion 
In conclusion, we have reported an efficient, catalyst free and water mediated synthesis 
of new coumarin derivatives having imidazo[1,2-a]pyridine moiety using Groebke-Blackburn-
Bienayme condensation reaction. Various 2-amino pyridine derivatives and isocyanides were 
used in this reaction. The final structure of the final product 4b was confirmed with X-ray 
diffraction analysis. The notable advantages of this protocol are water was employed as a 
reaction solvent, operational simplicity, easily available starting materials and no catalyst was 
employed. 
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